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THESIS ABSTRACT 
Symptoms of post-concussion syndrome (PCS) can occur after a mild traumatic 
brain injury (mTBI). Whilst specific neuropsychological tests can be used to 
determine cognitive disturbances, there is a reliance on the use of self-report 
measures to record the presence and severity of other PCS symptoms. Self-
reported symptoms can be subject to over report and exaggeration, particularly in 
individuals involved in litigation (Mittenberg, Patton, Canyock & Condit, 2002; 
Larrabee, 2003).  
Paper one investigated the research evidence relating to what is known about the 
validation of self-reported symptoms of PCS. A total of nine papers were identified 
and appraised, the findings were synthesised according to the following topic 
areas:  performance validity test outcomes and symptom reporting, the application 
of PCS self-report measures as symptom validity tests (SVTs), and the application 
of new and existing SVTs.  Paper two followed from a recommendation to 
investigate a new measure that involved the endorsement of both genuine 
symptoms and atypical symptoms of PCS.  This paper aimed to explore the utility 
of the Symptoms of Post-Concussion Syndrome questionnaire (SPCS).  A 
simulation design was employed using control participants instructed to respond 
genuinely, and participants instructed to malinger. An optimal cut off score of >25 
was established for the measure which produced promising diagnostic 
classification statistics (sensitivity .90, specificity 1.00, positive predictive power = 
100%, negative predictive power = 93.75%). Further validation of the proposed cut 
off score with a clinical sample is required. Finally, paper three provides a 
reflective account of the process of completing this thesis, and a discussion of the 
challenges that were encountered along the way.   
 
 
 
 
Total word count: 19,549 (excluding references and appendices)   
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PREFACE  
Paper one and paper two in this thesis will be submitted to the Journal of Clinical 
and Experimental Neuropsychology, which has an emphasis of interest on validity 
studies of psychometric procedures used in neuropsychological assessment of 
persons with known or suspected brain damage.  
Both papers have been written in accordance with the author guidelines (Appendix 
W) with the following exceptions: 
 Main tables and figures have been included in the main text of the thesis in 
order to improve readability.  
 All papers have been formatted in accordance with the guidelines provided 
by Staffordshire and Keele Universities for the submission of professional 
theses.  
The third paper in this thesis is not intended for publication.  
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Paper One: Literature Review  
How Can the Self-report of Post-Concussion 
Syndrome Symptoms be Validated?  
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ABSTRACT  
 
Introduction: Symptoms of post-concussion syndrome (PCS) can occur after a 
mild traumatic brain injury (mTBI). Diagnosis relies in part on the self-report of 
symptoms which can be subject to over-report and exaggeration. This article 
aimed to review the literature for what is known about the validation of self-
reported symptoms of post-concussion syndrome (PCS).  
Method: To identify articles that investigated symptom validity tests and/or factors 
that affect the legitimate self-report of PCS symptoms, a computerised literature 
search using EBSCO host (including All Health, Life Sciences and Psychology and 
Sociology databases) and Web of Science data bases was undertaken using the 
search terms - POST CONCUSS* or POSTCONCUSS* or POST-CONCUSS*, 
MALINGER*, and SYMPTOM VALIDITY. Papers were reviewed using an 
evaluative tool which contained items relating to reporting, generalisability, validity, 
and power. The findings from each paper were synthesised to better understand 
what is known about the self-report of symptoms in PCS.  
Results: A total of nine papers were selected for review. Research papers 
concerning the following topic areas were appraised and discussed:  performance 
validity test outcomes and symptom reporting, the application of PCS self-report 
measures as SVTs, and the application of new and existing SVTs.  
Conclusion: This review found that the self-report of PCS symptoms can most 
reliably be validated using SVT measures that function as clinical prediction rules 
and have high sensitivity, specificity, positive predictive power and negative 
predictive power values. The merits of papers concerned with the utility of self-
report measures of PCS symptoms as SVTs, as well as measures designed for 
the sole purpose of identifying over reporting, were discussed. Recommendations 
for future research included exploring the utility of a measure that looks at both 
over reporting of PCS symptoms and the endorsement of spurious or atypical 
symptoms not associated with PCS.  
 
Word count – 9639 (inclusive of 294 word abstract) 
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How Can the Self-report of Post-Concussion Syndrome Symptoms be 
Validated? 
What is Post-Concussion Syndrome? 
Post-Concussion Syndrome (PCS) is a set of psychological, somatic and cognitive 
symptoms that may occur after experiencing a concussion. Diagnostic criteria 
established by The International Statistical Classification of Diseases and Related 
Health Problems (ICD-10) states that in order to receive a diagnosis of PCS a 
patient must have had a head injury “usually sufficiently severe to result in loss of 
consciousness”, and then within four weeks, develop at least three of the following 
symptoms; headache, dizziness, fatigue, irritability, sleep problems, concentration 
problems, memory problems, problems tolerating stress/emotion/alcohol (World 
Health Organisation, 1992).  
Neuropsychological tests are used to measure cognitive deficits that can 
result from PCS, for example, memory problems. Self-report questionnaires are 
used alongside these tests to measure the presence and severity of other reported 
symptoms.  
When considering a diagnosis of PCS, clinicians must also evaluate the 
possibility of malingering and symptom exaggeration. Malingering refers to the 
intentional production of false or exaggerated psychological or physical symptoms, 
motivated by external incentives, for example, financial compensation (Bush, Ruff, 
Troster, Barth, et al., 2005). It is estimated that around 40% of individuals involved 
in litigation for head injury are malingering symptoms (Mittenberg, Patton, Canyock 
& Condit, 2002; Larrabee, 2003).  Undetected malingering can have clinical 
implications on receiving an accurate diagnosis, injury management, and can also 
lead to increases in health costs as well as blocking services for individuals 
experiencing genuine clinical symptoms (Logan, Goldman, Zola & Mackey, 2014).  
What is symptom and performance validity? 
In an article by Bush and colleagues in 2005, symptom validity is defined as ‘the 
accuracy or truthfulness of the examinee’s behavioural presentation, self-reported 
symptoms, or performance on neuropsychological measures.’ (Bush et al., 2005). 
This definition has since been refined, however. Confirmatory factor analysis by 
Van Dyke, Millis, Axelrod and Hanks (2013) revealed that cognitive performance, 
12 
 
symptom self-report, performance validity and symptom validity are distinct 
factors. This suggests that failure in one validity domain does not invalidate the 
other domain, and so performance validity and symptom validity should be 
evaluated separately.  It was recommended by Larrabee (2012) that the terms 
‘performance validity test’ (PVT) and ‘symptom validity test’ (SVT) be used as 
opposed to “effort” or “response bias”. It is proposed that performance validity 
refers to the degree to which an individual’s neuropsychological test performance 
is reflective of their actual cognitive ability. Symptom validity, however, is the 
degree to which an individual’s symptomatic complaint in response to self-report 
measures is reflective of their true experience of symptoms.  
Rationale for the current review 
Much controversy exists around the diagnosis of PCS (Al Sayegh, Sandford, & 
Carson, 2010).  This is due to disagreements over the aetiological mechanism and 
the finding that symptoms of PCS also occur in individuals who have no history of 
head injury (Iverson, 2005). There has been much debate concerning the degree 
to which psychological factors and organic factors are responsible. The World 
Health Organisation (Carroll et al., 2004) conducted a systematic review of the 
prognosis for mild traumatic brain injury (mTBI) and concluded that persistent PCS 
symptoms following an mTBI involves a complex interplay of biological, 
psychological, and social factors, including compensation and litigation issues. An 
editorial article in the British Journal of Psychiatry (King, 2003) cited the possibility 
that, at different times after injury, ‘windows of vulnerability’ emerge which 
increase the role of psychological factors. Such factors include when the patient 
begins to doubt the possibility of recovery or when issues surrounding 
compensation claims predominate. As such, there is a need to systematically 
identify and evaluate the literature to understand the ways in which the validity of 
self-reported symptoms of PCS can be determined.  
Aim 
This review aims to explore and critically appraise the literature concerning what is 
known about the validation of self-reported symptoms of PCS. It focuses on 
synthesising the findings of the reported outcomes from the identified literature.  
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METHOD 
Selection of papers 
The final literature search was completed on 17/02/2017. To identify potential 
papers for review, a search strategy to search paper abstracts used the following 
search terms: POST CONCUSS* or POSTCONCUSS* or POST-CONCUSS*, 
MALINGER*, and SYMPTOM VALIDITY. As can be seen in Figure 1, this 
produced 41 results in EBSCO Host (which included the following databases: 
Psycinfo, AMED, MEDLINE, SPORTDiscus, AgeLine, and CINAHL) and 22 results 
in Web of Science.  Duplicate results were removed and the remaining abstracts 
were then reviewed to select the final nine papers that were to be appraised for 
this literature review. Samples of the papers were checked against the 
inclusion/exclusion criteria by another member of the research team to ensure the 
same papers were retained.  
Inclusion criteria 
Papers that met the following criteria were considered for review: 
 Papers that specifically referred to testing the validity of self-reported 
symptoms of PCS. 
 Papers that specifically referred to testing the utility of SVTs with PCS 
populations.    
 Papers that collected data using clinical samples or simulation designs with 
healthy participants.  
Exclusion criteria  
Papers that met any of the following criteria were excluded from the review: 
 Papers that concerned testing the validity of self-reported symptoms of TBI 
symptoms, without specifically referring to PCS. 
 Opinion papers or commentaries.  
 Poster presentations or conference proceedings that were not formally 
published as an empirical research paper.  
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Figure 1. Literature review screening process flow chart  
 
  
Full text articles accessed to assess 
eligibility (N = 12) 
Records identified through database searching (N = 63) 
EBSCO Host:   Web of Science: 
41    22 
Duplicates removed (N = 18) 
Search Terms 
POST CONCUSS*, POSTCONCUSS*, POST-CONCUSS*, MALINGER*, 
SYMPTOM VALIDITY 
Limiters 
Adults, English language 
Total number of papers for screening (N = 45)  
 
Papers removed on basis of 
title and/or abstract not 
meeting inclusion/exclusion 
criteria 
 (N = 33) 
Papers included in final review (N = 9) 
Papers removed on basis of 
inclusion/exclusion criteria   
(N = 3) 
 Study concerned with 
PVT measures and not 
SVT (n = 1) 
 Study did not specifically 
concern PCS (n = 2) 
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Evaluation tool 
In order to provide a critical appraisal of the papers included in this review an 
evaluation tool was developed as no single tool addressed the various study 
designs and methods of analysis (see appendix A). The evaluation tool was 
developed from two sets of appraisal checklists.  Three items were adapted from 
the Critical Appraisal Skills Programme (CASP) Evaluate a Clinical Prediction Rule 
Checklist (2013) and 11 items were adapted from Downs and Black (1999).  The 
tool has a total of 14 evaluative questions relating to reporting, applicability of 
findings, internal and external validity, and power. There are some questions on 
the tool that specifically relate to the evaluation of clinical prediction rules. Not all 
of the research papers in this review produce a clinical prediction rule, and so in 
order to allow for comparisons between research papers, these items on the tool 
have been designed to be optional, and thus only contribute to a paper’s 
evaluation score should it be applicable. It is believed that a percentage score will 
be more meaningful to the reader and this approach also allows for comparisons 
to be made across all the research papers included in this review.  
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RESULTS AND DISCUSSION 
The literature search retrieved a total of nine papers that met the inclusion and 
exclusion criteria. Two studies (Lange, Iverson, Brooks, & Ashton Rennison, 2010; 
Iverson, Lange, Brooks & Ashton Rennison, 2010) examined the effect of poor 
performance validity on the self-report of symptoms, two studies (Tsanadis, 
Montoya, Hanks, Millis, Fichtenberg, & Axelrod 2008; Van Dyke, Axelrod & 
Schutte, 2010) concerned investigations into the utility of existing self-report PCS 
symptom measures as SVTs, and five studies (Greiffenstein, Baker, Gola, 
Donders, & Miller, 2002; Cooper, Nelson, Armistead-Jehle, & Bowles, 2011; 
Lange, Edmed, Sullivan, French, & Cooper 2013; Sullivan, Lange, & Edmed, 
2016; Parks, Gfeller, Emmert, & Lammert, 2016) explored the application of new 
and existing symptom validity tests when assessing for PCS, using both known 
groups and simulation designs (Table 1). The reviewed papers have therefore 
been presented in three sections in order to synthesise findings, examine 
limitations, and draw conclusions from three different methods of assessing the 
validity of self-reported symptoms.  
The total percentage scores for each of the papers, along with the main 
strengths and limitations are presented in Table 2. For further detail concerning 
the appraisal of individual items on the evaluation tool for each paper, refer to 
Appendix B.  
 
Performance validity test outcomes and symptom reporting 
Two papers in the review focussed on the effect of scores on performance 
validity measures on the self-report of PCS symptoms. Lange, Iverson, Brooks 
and Ashton Rennison (2010) examined the influence of poor effort on self-reported 
PCS symptoms following mild traumatic brain injury (mTBI). The study evaluated 
responses from 63 participants seen in a specialty clinic for individuals who are 
slow to recover from an mTBI. Participants were divided into two groups based on 
their performance on the Test of Memory Malingering (TOMM; Tombaugh, 1996), 
a forced-choice performance validity test routinely used in neuropsychological 
assessments, where a ‘fail’ is suggestive of malingering.  It was hypothesised that 
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Table 1 
Characteristics of selected papers 
Reference  Country  Purpose/Aims Measure(s) Participants & Method   Findings  
(1) Lange, Iverson, 
Brooks, & 
Ashton 
Rennison (2010) 
Canada  To examine the 
influence of poor 
performance 
validity on self-
reported 
symptoms of PCS 
following mTBI 
Post-Concussion 
Scale (PCS; Lovell et 
al., 2006) 
British Columbia 
Cognitive Complaints 
Inventory (BC-CCI, 
Iverson, 2003a, 2003b; 
Iverson & Remick, 
2003) 
Test of Memory 
Malingering (TOMM; 
Tombaugh, 1996) 
63 patients from a 
concussion clinic 
Participants were divided 
into two groups based on 
their performance on the 
TOMM (fail n = 15, pass n 
= 48). Group differences in 
responses to self-report 
measures were then 
investigated.  
Significant main effects and 
large effect sizes were found for 
the PCS and BC-CCI total 
scores. Participants in the 
TOMM fail group scored higher 
than those in the TOMM pass 
group highlighting the 
importance of considering the 
influence of poor performance 
validity when assessing for 
PCS.  
(2) Iverson, Lange, 
Brooks & 
Rennison (2010) 
Canada To examine the 
“good old days” 
bias in patients 
who sustained 
mTBI. To explore 
the effect of 
performance 
validity on the 
report of pre-and 
post-injury PCS 
symptoms.  
British Columbia Post-
concussion Symptom 
Inventory (BC-PSI, 
Iverson & Gaetz, 2004; 
Iverson & Lange, 
2003; Iverson et al., 
2007) 
Test of Memory 
Malingering (TOMM; 
Tombaugh, 1996) 
90 mTBI participants and 
177 control participants.  
mTBI participants provided 
pre- and post-injury ratings 
on the BC-PSI. Ratings 
were also compared to 
healthy controls.  
mTBI participants endorsed 
fewer pre-injury symptoms in 
comparison to the control group. 
Individuals who failed the 
TOMM tended to retrospectively 
report fewer pre-injury and more 
post-injury PCS symptoms than 
those individuals who passed 
the TOMM.  
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(3) Tsanadis, 
Montoya, 
Hanks, Millis, 
Fichtenberg, & 
Axelrod (2008) 
USA To explore the 
frequency and type 
of PCS symptoms 
reported by 
individuals with 
moderate-severe 
TBI and to 
investigate the 
effects of poor 
performance 
validity on the 
report of 
symptoms. 
The Postconcussive 
Symptom 
Questionnaire (PCSQ; 
Lees-Haley, 1992) 
158 participants at a 
rehabilitation hospital. 
Participants were divided 
into two groups – 
moderate to severe brain 
injury (M-S TBI) (n = 133), 
and a mTBI group who 
exhibited poor 
performance validity (n = 
25). Participants’ 
responses on the PCSQ 
were compared for 
between group 
differences.  
Significant differences in item 
endorsement on the PCSQ 
were found. The mTBI poor 
performance validity group 
reported more symptoms with 
greater severity in comparison 
to the M-S TBI group.  
(4) Van Dyke, 
Axelrod, & 
Schutte (2010) 
USA To investigate the 
utility of the PCSQ 
and its short form 
versions as a 
symptom validity 
measure.  
The Post-concussive 
Symptom 
Questionnaire (PCSQ; 
Lees-Haley, 1992) and 
its short forms.  
Minnesota Multiphasic 
Personality Inventory-2 
Fake Bad Symptom 
Validity Scale (FBS; 
Lees-Haley, English, & 
Glenn, 1991) and the 
Response Bias Scale 
(RBS; Gervais, Ben-
Porath, Wygant, & 
Green, 2007). 
95 participants referred to 
a veteran’s medical centre. 
25 individuals were 
identified to be over 
reporting by the FBS and 
RBS. Total scores on the 
PCSQ were calculated and 
investigated with multiple 
regression analysis to 
determine construct 
validity. ROC curve 
analysis was conducted to 
determine the predictive 
value of the PCSQ.  
Multiple regression analyses 
revealed that self-report 
symptom validity scales 
predicted significant variance in 
PCSQ total scores. The PCSQ 
cut off score of >27 produced 
.36 sensitivity, .94 specificity, 
.69 PPP, and .80 NPP.    
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(5) Greiffenstein, 
Baker, Gola, 
Donders, & 
Miller (2002) 
USA To determine 
whether the FBS 
captured atypical 
reporting styles 
better than other 
infrequent-
symptom scales in 
the context of 
PCS. Explore the 
construct validity of 
the FBS.   
The Fake Bad Scale 
(FBS; Lees-Haley, 
English & Glenn, 1991) 
The Minnesota 
Multiphasic Personality 
Inventory – Second 
edition (MMPI-2; 
Butcher et al., 1989)  
 
159 litigating patients with 
illogical symptom histories 
termed the atypical minor 
head injury group (AMHI). 
A comparison group made 
of 68 patients with 
documented moderate-
severe closed head injury 
(MSCHI). All participants 
were administered a 
battery of tests and the 
correlational and 
diagnostic properties of the 
FBS were examined.  
The results indicated that when 
applying the original cutting 
score of 20+, the FBS was 
sensitive (.87) to atypical head 
injury symptoms, however 
specificity (.53) for the measure 
was lower, and the FBS items 
may reflect true long-term 
outcome in more severe TBI. 
The FBS appeared superior to 
other infrequency scales in 
differentiating atypical from real 
brain injury outcomes.    
(6) Cooper, 
Nelson, 
Armistead-
Jehle, & 
Bowles (2011) 
USA To investigate the 
psychometric 
properties of the 
mBIAS as a 
screening measure 
of symptom 
exaggeration for 
PCS.  
The mild Brain Injury 
Atypical Symptoms 
(mBIAS; Cooper et al., 
2011), The 
Posttraumatic 
Checklist-Military 
(PCL-M; Blanchard et 
al.,1996), The 
Neurobehavioral 
Symptom Inventory 
(NSI; Ciccerone & 
Kalmar, 1995).  
Subjects were 403 
consecutive referrals to a 
brain injury clinic at a large 
military medical centre. 
Factor analysis was 
performed on all items 
from the mBIAS, PCL-M, 
and NSI. Item 
endorsement on the 
mBIAS was used a marker 
for symptom over-
reporting. Diagnostic 
properties of the mBIAS 
were explored.  
Factor analysis revealed that 
the mBIAS scale items 
represented a unique factor. 
Psychometric properties of the 
mBIAS revealed that a total 
score of 8 on the measure was 
optimal for the detection of 
symptom over-reporting 
(sensitivity = .94, specificity = 
.92).  
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(7) Parks, Gfeller, 
Emmert, & 
Lammert (2016) 
USA To examine the 
accuracy of the 
SIMS in detecting 
participants 
instructed to 
simulate feigned 
PCS, PTSD and 
comorbid PCS and 
PTSD symptoms.  
The Structured 
Inventory of 
Malingered 
Symptomatology 
(SIMS; Widows & 
Smith, 2005), The 
Neurobehavioral 
Symptom Inventory 
(NSI; Ciccerone & 
Kalmar, 1995), The 
PTSD Checklist 
Civilian (PCL-C; 
Weathers et al., 1994).  
83 volunteer students were 
assigned to one of three 
experimental groups (1) 
feigned PCS (n = 26), (2) 
feigned PTSD (n = 26), (3) 
feigned PCS & PTSD (n = 
26). The sensitivity values 
at several cut off scores 
were examined.   
The SIMS produced the highest 
sensitivity values for the feign 
PCS group (.89). Other 
classification statistics were not 
available due to the study 
design not having a control 
group condition.  
(8) Lange, Edmed, 
Sullivan, 
French, & 
Cooper (2013) 
Australia  To examine the 
utility of the mBIAS 
to detect symptom 
exaggeration using 
a simulation 
design.  
The mBIAS (Cooper et 
al., 2011), the 
Minnesota Multiphasic 
Personality Inventory-
2, Restructured Form 
(MMPI-2-RF; Ben-
Porath & Tellegen, 
2008), the NSI 
(Cicerone & Kalmar, 
1995), the PCL-C 
(Weathers et al., 
1994), the SIMS 
(Widows & Smith, 
2005). 
85 undergraduate students 
were assigned to one of 
three experimental groups 
(1) feign PCS (n = 29), (2) 
feign PTSD (n = 32), (3) 
controls (n = 24). 
Participants received 
instructions according to 
their group condition. The 
diagnostic properties of the 
mBIAS were explored.  
Participants instructed to feign 
PCS and PTSD had significantly 
higher scores on the mBIAS 
than control participants. An 
optimal cut off score of >6 on 
the mBIAS was indicative of 
“possible exaggeration” and 
produced .62 sensitivity, .88 
specificity, .73 PPP, and .81 
NPP in controls vs. feign PCS 
comparisons.   
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(9) Sullivan, 
Lange, & 
Edmed (2016) 
Australia To evaluate the 
utility of the NSI 
Validity-10 to 
detect symptom 
exaggeration 
using a 
simulation 
design.   
The mBIAS (Cooper 
et al., 2011), MMPI-2-
RF (Ben-Porath & 
Tellegen, 2008), the 
NSI Validity-10 
(Vanderploeg, 
Cooper, Belanger, 
Donnell, Kennedy, 
Hopewell, & Scott, 
2014), the PCL-C 
(Weathers et al., 
1994), the SIMS 
(Widows & Smith, 
2005). 
Secondary analysis was 
performed on data from 
Lange et al. (2013) 
An optimal cut off score for 
the NSI Validity – 10 was 
identified as ≥10 which was 
indicative of “probable 
exaggeration” and produced 
.93 sensitivity, 1.00 
specificity, 1.00 PPP, and .96 
NPP in controls vs. feign PCS 
comparisons.   
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Table 2 
Research article strengths, limitations and percentage scores  
Reference  Percentage 
score  
Strengths  Limitations  
(1) 70% Clearly described aims & hypotheses, use of 
measures, recruitment and sampling of 
participants, statistical methods and main 
findings. 
Type 1 error (not corrected); Made assumptions about PVT 
outcomes and symptom validity; Issues with 
generalisability; Relied on results of single PVT measure.  
(2) 56% Clearly described aims & hypotheses, use of 
measures, statistical methods and main 
findings; Considered perceptions of pre-injury 
symptoms. 
Made assumptions about PVT outcomes and symptom 
validity; Issues with gernalisability and internal validity; 
Relied on results of single PVT measure.   
(3) 70% Clearly described aims & hypotheses, use of 
measures, recruitment and sampling of 
participants, and main findings.  
 Mod-severe TBI participants used as a comparison group; 
Between group differences were explored, but there was no 
exploration of the clinical utility of the measure; Made 
assumptions about PVT outcomes and symptom validity. 
(4) 67% Study design allowed for diagnostic 
classification statistics to be calculated; 
Provided two cut off scores to determine 
symptom validity; Examined variance explained 
by the measure using multiple regression 
analysis confirming construct validity.   
Veteran sample; Poor specificity values increasing the risk 
of false positives, lack of multiple methods to measure both 
cognitive and psychological domains; Measure may not be 
reliable in assessing validity of PCS in clinical population.  
(5) 57% Clear aims and hypotheses; Clear description of 
group demographics and construction of groups; 
Reported diagnostic classification statistics.  
Significant issues with study design/internal validity; Main 
outcome measures were not clearly described; High false 
positive rates, due to poor specificity; Not clear if measure 
is actually detecting differences in injury severity or 
malingering.  
(6) 71% Used factor analysis to confirm that measure Exclusively military sample; Lack of control group for 
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was representing a unique factor; Diagnostic 
classification statistics included with high 
sensitivity and specificity values.  
comparison; No convergent validity; Study cannot state that 
failure on the measure was a function of conscious 
attempts to exaggerate symptoms 
(7) 67% Promising initial findings for use of measure as 
an SVT; Clear aims/hypotheses, description of 
measure, statistical methods used, and main 
findings.  
No control group for comparison; Design did not allow for 
full diagnostic classification statistics to be calculated; 
Potential issues with generalisability due to simulation 
design.  
(8) 87% Utilised simulation design to allow for greater 
control in determining internal validity of the 
measure; Clear description and replicable 
method; reported diagnostic classification 
statistics including base rates.   
Reported sensitivity value relatively low; Statistical methods 
were not clearly outlined; Potential issues with 
generalisability due to simulation design; Requires further 
validation with a clinical sample. 
(9) 87% Clear description of development of measure. 
Provided classification statistics and diagnostic 
efficiency statistics for 25%, 35% and 45% base 
rates; High sensitivity and specificity reported.  
Statistical methods were not clearly outlined; Potential 
issues with generalisability due to simulation design; 
Requires further validation with a clinical sample. 
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patients who failed the TOMM would endorse a greater degree of self-
reported symptoms than those patients who passed the TOMM.  Self-report 
symptoms were measured by the Post-Concussion Scale (Lovell et al., 2006) 
and the British Columbia Cognitive Complaints Inventory (BC-CCI: Iverson, 
2003a, 2003b; Iverson & Remick, 2003).  
It was reported that significant main effects and large to very large 
effects sizes were found for the total scores on the Post-Concussion Scale (p 
= .002, d = 0.79) and BC-CCI (p = .011, d = 0.98). Participants in the TOMM 
fail group endorsed more symptoms than those in the TOMM pass group on 
both self-report measures. Lange et al. (2010) concluded that the results of 
their study highlight the influence of poor effort on self-report inventories and 
stated that it is critical to consider issues of poor effort and possible symptom 
exaggeration when making a diagnosis of PCS.  
Iverson and colleagues (Iverson, Lange, Brooks, & Ashton Rennison, 
2010) explored the “good old days” bias in a PCS population. The “good old 
days” bias was a term developed to describe the tendency of patients with 
injuries, or general trauma, to underestimate past problems and overestimate 
the degree of change that has occurred post injury. In this study, 90 patients 
receiving compensation benefits following a mild traumatic brain injury 
(mTBI) completed the TOMM and the British Columbia Post-concussion 
Symptom Inventory (BC-PSI; Iverson, Zasler & Lange, 2007), a 16-item 
measure designed to assess the presence and severity of PCS symptoms. 
Participants were asked to make current as well as retrospective symptom 
ratings on the BC-PSI based on the month prior to sustaining their mTBI. 
Responses were compared to a control group that consisted of 177 healthy 
adults. It was found that participants who failed the TOMM (28.8%) not only 
reported a higher number of post injury symptoms (p < .001; d=1.15), they 
also gave a more positive impression with regards to their experience of pre-
injury symptoms (p < .001; d=2.32) compared to patients who had passed 
the TOMM. Comparisons with the healthy control group revealed that all 
mTBI ratings of pre-injury symptoms, regardless of performance validity 
findings, were significantly lower than those reported by the control group (p 
< .001; d=0.65). However, a large effect size was found when comparing the 
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control group to the mTBI TOMM fail patients (p < .001; d=0.82) whereas a 
medium effect size was found for the mTBI TOMM pass patients (p < .022; 
d=0.46).  
Iverson et al. (2010) concluded that post-injury symptom reporting and the 
“good old days” bias was associated with performance validity testing results. 
The findings were explained as representing a systematic bias in which an 
individual is trying to create an impression of being more able and better 
functioning than the average person prior to their injury, and then 
exaggerating their symptoms following injury.  
Quality Assessment  
As can be seen in Table 2, using the evaluation tool, Lange et al. (2010) was 
given a percentage score of 70%, and Iverson et al. (2010) scored 56% with 
regards to the applicability of findings, internal and external validity, and 
power.   
One major limitation of these two papers is the suggestion that 
performance validity influences symptom validity. Conclusions are made 
about how performance validity testing, is important in establishing the 
legitimacy of self-reported symptoms of PCS, yet it is known that failure in 
one of these domains does not necessarily invalidate the results in the other 
(Van Dyke, et al., 2013). Although in Lange et al. (2010) and Iverson et al. 
(2010), the TOMM failure group endorsed more symptoms in comparison to 
participants who passed the TOMM, this did not necessarily mean that 
participants’ responses on the self-report measures were indicative of 
symptom invalidity. Conclusions can, therefore, only be made regarding the 
association of performance validity with the self-report of symptoms, and not 
causation. 
Participants  
All participants recruited in Lange et al. (2010) were receiving financial 
compensation. As a result it could be argued that the findings are not 
generalisable to the broader mTBI population due to the “litigation effect” as 
reported by Lees-Haley (1988). Issues with generalisability were also raised 
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in Iverson et al. (2010). It was stated that the sample should not be 
considered generalisable to all people who have sustained mTBIs as they 
were a highly selected and non-representative sample, who were also 
receiving compensation and were seen through a private clinic. 
Both papers reported potential issues of systematic bias. In Lange et 
al. (2010) it was stated that only 63 out of 151 patients actually received 
neuropsychological screening at the specialty clinic, and the data from these 
63 patients then went on to be analysed in the study. Similarly in Iverson et 
al. (2010), 62 out of 90 patients actually received neuropsychological 
screening. The samples that were used in the two studies may have 
represented sub-groups and a systematic bias of patients who were more 
likely to undergo neuropsychological screening, due to reporting more 
symptoms in the first instance, for example.  
Internal Validity 
Comparison analyses in Iverson et al. (2010) of the mTBI group’s reports of 
pre-injury symptoms to that of the control group, a large effect size was 
found for mTBI TOMM fail participants, however, a medium effect size was 
also found for the mTBI TOMM pass participants. Although the observed 
effect size was smaller for the TOMM pass than the TOMM fail, if the 
underestimation of pre-injury symptoms was solely associated with 
performance validity, a significant effect should not have been observed in 
participants classified as having legitimate performance validity, i.e. the 
TOMM pass group. This may suggest that experiencing an mTBI also has an 
impact on the “good old days” bias. 
There may be an issue with the statistical methods that were used in 
Lange et al. (2010) to compare the TOMM pass and TOMM fail groups. The 
authors reported that Mann-Whitney U tests were performed to look at group 
differences in symptom reporting on each item of the Post-Concussion Scale 
and BC-CCI. It is acknowledged that the probability of Type 1 error increases 
when multiple statistical comparisons are made and adjustments to the p 
value would help to correct for this. However, the authors then go on to state 
their decision not to apply a more conservative p value as this was 
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considered too stringent given the sample size.  The results reported by 
Lange and colleagues (2010), therefore, may have been affected by an 
increased probability of a Type 1 error. 
Measures  
Both Lange et al. (2010) and Iverson et al. (2010) made use of only a single 
PVT measure in order to assign participants to pass or fail groups. Previous 
research has questioned the TOMM’s sensitivity to correctly identify 
individuals who are giving poor or inadequate effort (DenBoer & Hall, 2007). 
It is possible that some participants may have been misidentified in the 
study, although the authors argue that this would not have changed the 
overall results of the study. Out of the 63 participants in Lange et al. (2010), 
just 15 (23.8%) were identified as failing the TOMM, and 16 (25.8 %) out of 
the 62 evaluated patients failed the TOMM in Iverson et al. (2010). This is 
not in keeping with previous research suggesting that around 40% of mTBI 
claims were indicative of probable malingering (Mittenberg, et al., 2002; 
Larrabee, 2003).  The small sample size in the TOMM fail groups draws to 
question whether the sample was representative of patients with mTBI, who 
are seeking compensation and fail performance validity tests. Furthermore, 
issues with the sensitivity of the TOMM may explain the medium effect size 
found in Iverson et al. (2010) in the comparison of pre-injury ratings between 
the control group and mTBI TOMM pass group, as it is possible that some 
participants were misclassified. 
The utility of existing self-report PCS symptom measures as SVTs  
The findings of two papers included in the review were concerned with the 
utility of an existing self-report measure, routinely used to assess the severity 
PCS symptoms. The Post-Concussive Symptom Questionnaire (PCSQ; 
Lees-Haley, 1992) is a 44 item self-report questionnaire that was initially 
developed to better understand the base rate occurrence of symptoms 
associated with PCS. Tsanadis, Montoya, Hanks, Millis, Fichtenberg and 
Axelrod (2008) used the PCSQ to examine differences in symptom reporting 
in two patient groups; individuals diagnosed with moderate to severe brain 
injury (n = 133), and individuals meeting criteria for mild traumatic brain injury 
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(mTBI) who exhibited no evidence of neurological injury and had failed tests 
of effort (n = 25). Tsanadis and colleagues (2008) found that participants in 
the poor effort mTBI group who were involved in litigation reported a higher 
degree of post concussive symptoms (psychological, cognitive, and somatic) 
than the moderate to severe TBI group. The authors stated that this was 
suggestive of symptom exaggeration and over reporting, and raised 
questions about PCS as a valid clinical diagnostic syndrome. The study 
highlighted observed differences in the reporting of symptoms of PCS 
between the two groups, but did not go on to suggest how the PCSQ could 
be used to establish the validity of symptom reporting.  
Research by Van Dyke, Axelrod and Schutte (2010) looked into the 
utility of the PCSQ as an SVT in 95 individuals referred to a veterans medical 
centre for neuropsychological evaluation. Firstly, the construct validity of the 
PCSQ was investigated with multiple regression analyses against other 
measures of cognitive performance, general distress, and self-report 
symptom validity. Secondly, ROC curve analyses were conducted to explore 
the predictive value of the PCSQ in identifying individuals who had failed 
other measures of validity; the Minnesota Multiphasic Personality Inventory-2 
Fake Bad Symptom Validity Scale (FBS; Lees-Haley, English, & Glenn, 
1991) and the Response Bias Scale (RBS; Gervais, Ben-Porath, Wygant, & 
Green, 2007). Van Dyke and colleagues (2010) aimed to investigate the 
utility of the PCSQ and two other short forms of the measure (PCS-19, Millis, 
Hanks, Fitchenberg, & Axelrod, 2007; and PCS-NIM, Tsanadis, Montoya, 
Millis, Hanks, Fitchenberg, & Axelrod, 2007). 
It was found that cognitive impairment did not account for significant 
variance in any of the versions of the PCSQ (PCSQ total = 2%, PCS-19 = 
4%, & PCS-NIM = 2%). Measures of symptom validity were found to account 
for the most variance in the model (PCSQ total = 42%, PCS-19 = 43%, & 
PCS-NIM = 43%). Receiver Operating Characteristic (ROC) curve analyses 
revealed that for the PCSQ total a cut-off score of >27 produced the highest 
specificity (.94) and the best hit rate (.79), this was at the expense of lower 
sensitivity (.36), however. A cut-off score of >22 produced optimal sensitivity 
(.80) and specificity (.77). Similar classification rates were found across the 
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short form versions of the PCSQ, indicating that no one index is statistically 
superior. Van Dyke and colleagues (2010) therefore suggested that the short 
form versions perform just as well in comparison with the benefit of having 19 
items rather than 44. It was concluded that the PCSQ and its short forms 
perform well as SVTs.  
Quality Assessment  
Tsanadis et al. (2008) received a percentage score of 70%.  The study was 
well reported and gave a clear overview of the impact of injury severity and 
litigation status on the self-report of post concussive symptoms. The study by 
Van Dyke et al. (2010) was evaluated as 67%. 
Participants  
Tsanadis et al. (2008) used a moderate-severe TBI group as a comparison 
with the mTBI sample. There was no information regarding the self-
awareness of symptoms collected in the study which could be considered 
problematic as symptom reporting requires self-awareness as well as self-
report. It could be argued that the moderate to severe TBI group participants 
had deficits in self-awareness and thus their ability to accurately report 
symptoms would have been compromised, which could explain the 
differences observed between the two groups.  
A main limitation of Van Dyke et al. (2010) was the generalisability of 
the findings, given the exclusively military veteran sample. Of the 95 
participants, 92% were male. There is also some concern over the referral 
questions that were included in the sample. 54% of participants were 
referred to the service for TBI, 13% mild cognitive impairment, 5% 
cerebrovascular disease, 2% multiple sclerosis, and 2% hypoxia. Psychiatric 
referrals were also included which accounted for 23% of the sample. The 
data from the TBI participants was not reported separately to the rest of the 
sample. Although the paper by Van Dyke et al. (2010) meets the inclusion 
criteria of this literature review, as it concerns the self-report of PCS 
symptoms with a clinical sample, it is problematic to draw conclusions about 
the suitability of the PCSQ (and its short form versions) as an SVT in the 
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assessment of PCS, due to the variety of conditions and presentations 
included in the sample. 
Design and statistical analysis methods 
The research design and analysis methods of Tsanadis and colleagues 
(2008) did not allow for a clinical prediction to be made. Inferences 
concerning the differences between group scores were developed and it was 
argued that the findings provided evidence that the self-report of PCS 
symptoms, in the presence of poor effort and involvement with litigation, may 
be viewed as negative impression management. However, as discussed 
earlier, caution should be taken when considering the relationship between 
performance validity, and symptom validity.   
The research design used in Van Dyke et al. (2010) allowed for the 
findings to be used to examine the PCSQ for its utility as an SVT using 
diagnostic and classification statistics, which demonstrated some promising 
early evidence for its use as a brief measure. The lack of multiple methods of 
measuring both cognitive and psychological domains is considered a 
limitation of Van Dyke et al. (2010), as shared-methods variance may have 
affected the results. Cognitive symptoms were measured only by 
neuropsychological assessment measures whereas symptom validity and 
general distress were measured by self-report measures. The variance that 
was explained by the regression model could have been attributed to the 
measurement methods rather than the constructs that the measures were 
assumed to represent. Van Dyke and colleagues (2010) commented 
however, that the small amount of variance that was explained by the 
addition of distress measures to the model suggested that the findings were 
not spurious. 
The application of new and existing symptom validity tests  
Five papers evaluated the application of measures designed to assess the 
validity of the self-report of PCS symptoms. Cooper, Nelson, Armistead-
Jehle, & Bowles (2011) developed the 5-item Mild Brain Injury Atypical 
Symptoms Scale (mBIAS) to detect symptom exaggeration when embedded 
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within commonly used screening instruments used in PCS and PTSD (Post 
Traumatic Stress Disorder) populations. The mBIAS consists of the following 
items, (1) being unable to hear anything [complete deafness] for periods of 
time; (2) seeing only in black and white; (3) completely losing your voice for 
more than a minute; (4) complete loss of feeling in both arms; (5) difficulty 
swallowing due to a lump in the throat. Respondents are required to rate the 
extent to which the symptoms have disturbed them over the last two weeks 
on a 5-point likert scale (1= not at all, 5= extremely). A total score is then 
obtained. Cooper et al. (2011) used consecutive referrals to a brain injury 
clinic at a military medical centre to explore the psychometric properties of 
the mBIAS as an SVT with mTBI and neurologic patients. The purpose of the 
inclusion of a range of neurological conditions as well mTBI was to reduce 
the potential for false errors on the mBIAS by ensuring that item 
endorsement was not commonly shared with severe diffuse impairments. 
Patients completed measures of symptoms of PTSD, and PCS as well as the 
mBIAS items which were interspersed within the content of the other 
measures to minimise the likelihood of detection.  
Factor analysis revealed that the mBIAS items measure a unique 
dimension in symptom reporting and so mBIAS responses should not be 
confounded by the presence of PTSD or PCS. Cooper et al. (2011) stated 
that given that the items on the mBIAS were extremely unlikely to be caused 
by mTBI, any endorsement of items should be considered as a marker for 
symptom over-reporting. The cut-off score with the best balance of sensitivity 
and specificity, positive predictive power and negative predictive power, 
however, appeared to be an mBIAS score of ≥8. This led to a sensitivity 
value of .94, and a specificity value of .92. Cooper and colleagues (2011) 
concluded that the findings show strong initial support for the use of the 
mBIAS in military post-deployment populations.  
Greiffenstein, Baker, Gola, Donders and Miller (2002) aimed to use 
archival data to conduct further research into the Fake Bad Scale (FBS; 
Lees-Haley, English & Glenn, 1991) to determine whether it was specific to 
persons trying to malinger a personal injury in the context of PCS.  The FBS 
is a 43-item self-report measure that was constructed to detect simulation of 
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emotional distress in the context of compensation seeking. A cut-off score of 
20 more was proposed to determine the validity of self-reported symptoms. 
Participants included a pool of 159 litigating patients with illogical symptom 
histories, termed the atypical minor head-injury (AMHI) group, the authors 
had also assessed this group as having ‘persistent post-concussion 
syndrome’. The AMHI group was compared to a group of 68 patients with 
documented moderate-severe closed head injury (MSCHI). All patients had 
been administered a battery of PVTs and SVTs, including the FBS. The 
results indicated that when applying the original cutting score of 20+, the 
FBS was sensitive (.87) to atypical head injury symptoms, however, 
specificity (.53) was 53%, indicating a false positive rate of 47%. 
Greiffenstein and colleagues (2002) commented that the MSCHI participants 
were also involved in seeking compensation and so part of this group may 
have engaged in symptom promotion or exaggeration in excess of their 
legitimate injuries. Following correlations of FBS scores and indices of 
neurological status, it was found that FBS items overlapped with objective 
neurological abnormalities that may be seen within a moderate-severe head 
injury group. It was therefore concluded that the original FBS cut-score of 
20+ may incorrectly identify individuals with more severe head injury as over 
reporting symptoms, as some FBS items may reflect true long-term outcome 
in severe cerebral dysfunction. An alternative cut-off score of 24+ was 
suggested for this patient group. The FBS does however, appear to be a 
valid measure of detecting spurious symptom reporting in the context of PCS 
patients seeking compensation.  
Analogue simulation designs: 
Within the group of papers evaluating the application of existing SVTs to 
assess the validity of self-reported symptoms of PCS, a subsection emerged 
concerning the use of analogue simulation designs. Analogue simulation 
designs use non-clinical participants who are assigned to different 
experimental conditions (e.g. control group and instructed to malinger group) 
and responses on the test measure(s) of interest are compared and 
analysed. The American Academy of Clinical Neuropsychology Consensus 
Conference Statement on the neuropsychological assessment of effort, 
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response bias and malingering (Heilbronner, Sweet, Morgan, Larrabee, Millis 
& Conference Participants, 2009) states that simulation designs represent 
rigorous and clinically relevant research designs.  Such designs provide tight 
experimental control for examining “proof of concept”, including when 
validating new diagnostic or screening measures (Streiner, 2003).  
The Structured Inventory of Malingered Symptomatology (SIMS: 
Widows and Smith, 2005) is a 75-item SVT designed as a screening 
measure to detect exaggerated psychological and neurological symptoms. 
Parks, Gfeller, Emmert and Lammert (2016) aimed to examine the accuracy 
of the SIMS in detecting participants instructed to simulate feigned PCS 
symptoms, PTSD symptoms, and comorbid PCS and PTSD symptoms. 78 
undergraduate students were recruited and randomised into one of three 
experimental groups: (1) feigned PCS symptoms, (2) feigned PTSD 
symptoms, and (3) feigned PCS and PTSD. Participants were asked to 
imagine they had been in a car accident in which they were unharmed. As a 
result of the accident they were involved in a personal injury lawsuit and 
were required to undergo psychological testing and if found to have 
sustained an injury could receive compensation. Participants were also 
provided with a list of symptoms for their respective disorder. All participants 
were administered the SIMS (Widows & Smith, 2005), the Neurobehavioral 
Symptom Inventory (NSI: Cicerone and Kalmar, 1995) – a checklist for PCS 
symptoms, and the PTSD Checklist Civilian Version (PCL-C: Weathers, Litz, 
Huska, and Keane, 1994) – a symptom checklist for the assessment of 
PTSD.  
Parks and colleagues (2016) explored the sensitivity of the SIMS with 
the different experimental groups.  A cut-off score for the SIMS total score of 
>14 detected the greatest number of participants in the feigned PCS group 
(.89). The authors concluded that the SIMS has potential for use in clinical 
settings where PCS symptoms are assessed and there is a need for 
symptom validity testing.  
Lange, Edmed, Sullivan, French and Cooper (2013) used an analogue 
simulation study design to examine the utility of the mBIAS to detect feigned 
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PCS and PTSD. For a full description of the mBIAS, see the discussion of 
Cooper et al. (2011) above. 85 healthy undergraduate students were 
recruited. Participants completed a battery of self-report measures following 
random allocation to one of three experimental conditions: control group, 
feigned symptoms of PCS, and feigned symptoms of PTSD. The battery of 
self-report measures included the mBIAS (Cooper et al., 2011), the PCL-C 
(Weathers et al., 1994), the NSI (Cicerone & Kalmar, 1995), The Minnesota 
Multiphasic Personality Inventory-2, Restructured Form (MMPI-2-RF; Ben-
Porath & Tellegen, 2008), and the SIMS (Widows & Smith, 2005). In this 
study the mBIAS, NSI and PCL-C were combined into a single measure. 
This was done in an effort to minimise the likelihood of item detection. Prior 
to completing the self-report measures, participants received written 
instructions for their experimental condition. For the PCS and PTSD 
conditions the instructions consisted of a case scenario that described their 
motivations for feigning and diagnostic criteria for either PCS or PTSD. A test 
phase was also incorporated to ensure participants had sufficient 
understanding of the disorder they were instructed to feign.  
All participants were informed of an incentive of $100 depending on 
their performance. Control participants were informed that they could win the 
prize based on the honesty of their responses. While the PCS and PTSD 
groups were told that winners would be selected based on the quality of their 
feigned performance, in actual fact, prize winners were randomly selected.   
A series of group comparisons were undertaken to examine the 
differences in group responses to the psychometric measures. Lange et al. 
(2013) acknowledged the probability of type 1 error increasing with multiple 
comparisons and so significant between group differences were interpreted 
using a criteria of p <.01. Participants in the feign PCS and feign PTSD 
groups were found to have consistently higher scores on all of the self-report 
measures in comparison to the control group, with large to very large effect 
sizes. Analyses on the mBIAS responses revealed that feign PCS 
participants had higher total scores (p < .01; d = 1.02) and a significantly 
higher number of symptoms endorsed as ‘severe’ or higher (p < .01; d = .84 
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to d = 1.59). One of the five mBIAS items in particular received higher scores 
[“being unable to hear anything (complete deafness) for periods of time”]. 
Classification statistics identified the optimal cut-off score for “highly 
probable exaggeration” for the feign PCD group as ≥8. This produced very 
high positive predictive power (1.00) and specificity (1.00), and moderate 
negative predictive power (.73), sensitivity, however was low (.31). An 
optimal cut-off score for “possible exaggeration” was determined as ≥6. This 
produced a moderate-high positive predictive power (.73) and adequate 
specificity (.88) and negative predictive power (.81). Sensitivity improved with 
this cut-off to .62. Lange et al. (2013) concluded that the “highly probable 
exaggeration” cut-off score is only reliable as a tool to “rule in” symptom 
exaggeration, but is not reliable as a measure to “rule out”. The second cut-
off score of ≥6 however, can be used as a tool to “rule out” symptom 
exaggeration. That is, a clinician can have reasonably high confidence that 
an individual scoring below the cut-off score is not exaggerating. This cut-off 
score will identify a considerably larger proportion of individuals feigning PCS 
symptoms than the first cut-off score. 
Sullivan, Lange & Edmed (2016) performed secondary analysis on the 
data from Lange et al. (2013) to explore the utility of the Neurobehavioral 
Symptom Inventory Validity – 10 index (NSI Validity-10; Vanderploeg, 
Cooper, Belanger, Donnell, Kennedy, Hopewell, & Scott, 2014) to detect 
symptom exaggeration in PCS and PTSD.  The same participants and 
procedures as described in Lange et al. (2013) were used. New NSI validity 
measures were created in 2014 by Vanderploeg et al. This included the 
LOW6, which was made up of 6 low-frequency items; The Negative 
Impression Management-5 (NIM5), made up of 5 negative impression 
management items; and the NSI Validity-10 which was made up of 10 items 
from the LOW6 and NIM5 (one overlapping item was counted once).  
An optimal cut-off score for “highly probable exaggeration” was ≥10 
which in the feign PCS condition produced very high positive predictive 
power (1.00), specificity (1.00), negative predictive power (.96), and 
sensitivity (.93). The optimal cut-off score for “possible exaggeration” was ≥8 
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which gave high positive predictive power (.93), specificity (.96), negative 
predictive power (.98), and sensitivity (.97). These results suggested that the 
NSI Validity -10 was a very effective measure at accurately identifying 
feigned PCS.  
Quality Assessment  
Participants  
There was some concern about the selection of participants in Lange et al. 
(2013) and Sullivan et al. (2016). Participants across all groups were 
selected for the final sample based on their responses on the SIMS and the 
MMPI-2-RF validity scales. Control group participants were excluded from 
the study if their responses did not suggest a genuine response style. 
Participants in the experimental conditions however, were also excluded if 
their responses did not suggest that they had over reported or exaggerated 
symptoms enough (scoring beyond the cut-offs on both measures). It is 
possible that by narrowing the sample in this way, only participants with the 
most extreme reporting styles were retained, and less extreme, more subtle 
‘feigners’ were not represented. This could have impacted on the likelihood 
of finding statistically significant results as the control group and 
experimental conditions became more polarised. It is important, particularly 
in analogue simulation designs, that a broad range of response styles be 
included in the analysis, as this is more likely to be reflective of the range of 
malingering presentations in real life settings.   
The sample used in Cooper et al. (2011) was composed of active duty 
service members, which may have led to some issues with the 
generalisability of findings to clinical settings as the motivation to feign 
symptoms may differ. As part of an analogue simulation design, Lange et al. 
(2013), Sullivan et al. (2016), and Parks et al. (2016) recruited neurologically 
healthy participants. There may be some issues with the generalisability of 
the findings from this population to clinical settings. Potential issues 
surrounding the generalisability of using these designs are discussed in more 
detail below. 
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Generalisability of analogue simulation designs.  
The implications of using an analogue simulation study design, as seen in 
Lange et al. (2012), Parks et al. (2016), and Sullivan et al. (2016) is 
discussed. An advantage of using an analogue simulation design is that 
there is greater experimental control than with other samples. Lange and 
colleagues (2010) acknowledged however, that the most ecologically valid 
study design when validating a new psychometric measure would be to use 
clinical subjects alongside known groups in a simulation design. As such, it 
could be argued that these studies lack ecological validity and 
generalisability. Compared with previously proposed cut-off scores 
developed from research using clinical populations, the cut-off scores 
identified by Sullivan et al. (2016) were very low. Previous studies with 
clinical criterion designs, suggest cut-off scores of ≥23 to detect over 
reporting of symptoms (Lange, Brickell, Lippa, & French, 2015; Vandeploeg 
et al., 2014). It could be argued that these studies were not specifically 
investigating the feigning of PCS symptoms, however, and so a lower cut-off 
score may be acceptable and appropriate when identifying feigned self-
reported PCS symptoms. Sullivan et al. (2016) argue that different measures 
used to diagnostically categorise the participant groups may explain the 
differences in cut-off scores found in the clinical studies.   
Several studies have found that simulators instructed to malinger do 
not significantly differ from clinical populations seeking secondary gain 
(Meyers, 2007; Mittenberg, Theroux-Fichera, Zielinski, & Heilbronner, 1995; 
Rohling, Meyers, & Millis, 2003).   
Study Design 
There were issues with the study designs employed in Cooper et al. (2011) 
and Parks et al. (2016). Neither study recruited a control group for 
comparison. This meant that for Parks et al. (2016) additional classification 
statistics (i.e. specificity, positive and negative predictive power) could not be 
calculated. Specificity and predictive power calculations are required to 
ensure that a measure does not incorrectly identify genuine responders as 
having invalid self-report of symptoms. The authors acknowledged this 
39 
 
limitation and stated that the reported findings are part of an early step in 
validating the SIMS for use as an SVT with PCS populations. Classification 
statistics were still calculated in Cooper et al. (2011) however, as it was 
assumed that any endorsement of items on the mBIAS was a marker for 
over reporting. The study design did not include the use of any established 
SVTs which could have allowed for convergent validity comparisons. 
Consequently, Cooper et al. (2011) cannot state with confidence that over-
reporting on the mBIAS is a function of conscious attempts to exaggerate 
symptoms. The findings in the study cannot be used to establish why a 
patient may endorse items on the mBIAS and be identified to have elevated 
scores. 
The design employed by Greiffenstein et al. (2002) appears to 
confuse the findings of the effectiveness of the FBS to determine symptom 
validity. It is reported that alongside the FBS, other measures of validity were 
also collected. The results of these measures however, were not used to 
classify participants into either a feigning or genuine responders group. The 
reported classification statistics were based on differentiating the AMHI 
group from the MSCHI group, yet the MSCHI were also involved in litigation 
and may have also engaged in symptom promotion, and this may explain the 
poor specificity values that were found. This also draws into question 
whether the FBS was classifying individuals based on invalid symptom 
reporting or rather, if it was differentiating based on the severity of expressed 
symptoms. The finding that FBS items overlapped with neurological 
symptoms that may be seen with more severely injured patients supports this 
hypothesis. The reliability and validity of the FBS as an SVT is therefore, 
questionable. It is noted that Greene (2000) questions the validity of the FBS 
stating that “additional research is needed to determine whether the FBS 
scale is specific to persons trying to malinger in personal injury because of its 
low correlations with other infrequency scales” (pp. 76-77). Further research 
with an alternative comparison group, or a simulation design that warrants 
greater experimental control may help to determine what the FBS is in fact 
measuring.   
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Synthesis of Findings  
The papers in this literature review were presented in three sections 
according to the types of measures used to establish the validity of self-
reported symptoms of PCS. The findings from these three sections are 
synthesised below.   
Performance validity test outcomes and symptom reporting 
The two research papers (Lange et al., 2010; Iverson et al., 2010) that 
explored the relationship between performance validity and symptom 
reporting in PCS provided little information in the way of determining valid 
self-report due to performance validity and symptom validity being distinct 
from one another. Clinicians may carry out PVTs as part of a standard 
neuropsychology assessment, and this will provide information about the 
validity of performance on other neuropsychological measures. In order to 
establish the validity of self-reported symptoms, however, SVTs are needed. 
Self-reported symptoms cannot be reliably validated using outcomes from 
PVT measures to assume symptom validity. 
The utility of existing self-report PCS symptom measures as SVTs  
There is scope for existing self-report measures, such as the PCSQ 
(Tsanadis et al., 2008; Van Dyke et al., 2010), to be utilised to assess the 
validity of self-reported PCS symptoms. Study designs that compare the 
effectiveness of self-report measures with existing SVTs and provide cut-off 
scores with classification statistics enable greater clinical application than 
designs that solely identify between group differences. Van Dyke et al. 
(2010) proposed a cut-off score on the PCSQ of >22, which provided 
adequate specificity (.94), however, sensitivity (.36) was poor, meaning that 
many cases of invalid self-report of PCS symptoms would go undetected.    
The utility of new and existing SVTs 
The FBS was found to have promising concordant validity with other 
established SVT measures (Greiffenstein et al., 2002) and was effective at 
detecting atypical persistent PCS patients from a moderate-severe closed 
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head injury comparison group. However, as the comparison group were also 
involved in litigation, it is not clear if the FBS was in fact measuring symptom 
validity. As a high rate of false positives were found it is likely that the FBS 
was measuring symptom validity and that the two groups did not represent a 
malingering group and a genuine responders group, however, positive 
correlations were also found with features of true long term outcome of more 
severe injuries.     
Initial research into the mBIAS presented promising findings regarding 
its use as an SVT to determine the validity of self-reported PCS symptoms 
(Cooper et al., 2011), however due to the study design it could not be stated 
with confidence that the mBIAS measured conscious attempts to exaggerate 
PCS symptoms. A simulation study using the mBIAS allowed for greater 
control to investigate the internal validity of the measure (Lange et al., 2013). 
Although acceptable levels of specificity were attained, the sensitivity (.62) of 
the mBIAS in detecting the self-report of feigned PCS symptoms was 
disappointing, suggesting that the measure may not be as effective at 
determining symptom validity as Cooper et al. (2011) suggested. The SIMS 
(Parks et al., 2016) provided a better sensitivity value of .89, supporting its 
use as an SVT screening measure in PCS. Further classification statistics 
could not be calculated however, due to the lack of a comparison group.  
Of the papers reviewed in this section, the NSI Validity – 10 was found 
to be the most effective measure at validating the self-report of PCS 
symptoms (Sullivan et al., 2016). The classification statistics revealed that a 
cut off score of ≥8 produced high sensitivity (.97), specificity (.96), PPP (.93), 
NPP (.98).  
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CONCLUSION 
This review identified, critically appraised and synthesised the literature to 
understand how the self-report of PCS symptoms can be validated. A review 
of the literature led to the identification of nine research articles. Appraisal of 
these research papers resulted in three main sections of the review, each 
section concerned different categories of measures to validate the self-report 
of PCS symptoms. These included the effect of PVT outcomes on symptom 
reporting, the application of self-report PCS symptom measures as SVTs, 
and the application of new and existing SVTs.  
Clinical Implications 
According to statistics released by Headway (2012), each year around 1 
million people attend accident and emergency services in the UK following a 
head injury. Approximately 85% of these are cases of mTBI. At least half of 
these patients will experience some PCS symptoms, and although most will 
recover completely within 3 months of injury, around a third experience 
persisting PCS symptoms beyond this time (King, 2003). Due to the reliance 
on the self-report of symptoms in the diagnosis of PCS, determining 
symptom validity is of great importance. This is particularly pertinent for 
services involved with neuropsychological assessment for the purposes of 
litigation. Knowledge of effective measures of SVTs that can detect feigned 
symptoms of PCS is essential and these measures should be included in 
standard psychometric batteries when considering a diagnosis of PCS.  
Future Research  
All of the SVT measures that were investigated through this review were 
concerned with the endorsement of either genuine symptoms or atypical 
symptoms of PCS. An area for future research could involve an investigation 
into the design of a measure that includes both genuine symptoms of PCS 
and atypical pseudo symptoms in order improve the effectiveness of the 
measure to detect different styles of malingering.  As discussed earlier, 
simulation designs appear to be suitable for establishing the utility of new 
measures as greater experimental control can help to determine reasons 
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behind symptom endorsement. As with the validation of any psychometric 
measure, however, evidence of suitability with the intended clinical 
population is also of importance in order to ensure generalisability. 
The British Psychological Society (2009) reported that there is little UK 
research literature on validity testing and that there is a need for this to be 
developed. This literature review has revealed that in terms of studies 
investigating the validation of the self-report of PCS symptoms, no UK 
research currently exists.  
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Appendix A 
Evaluation Tool  
Reporting 
Is the hypothesis/aim/objective of the 
study clearly described? 
Yes No 
Are the main outcomes to be measured 
clearly described in the introduction or 
methods section? 
If the main outcomes are first mentioned 
in the Results section, the question 
should be answered No.  
 
Yes No 
Are the characteristics of the 
participants included in the study 
clearly described? 
In cohort studies and trials, inclusion and 
exclusion criteria should be given.  
 
Yes No 
Are the statistical methods used clearly 
described? 
 
Yes No 
Are the main findings of the study 
clearly described? 
Simple outcome data should be reported 
for all major findings so that the reader 
can check the major analyses and 
conclusions.  
 
Yes No 
Can the performance of the clinical 
prediction rule be calculated? 
Performance results can be presented as: 
sensitivity, specificity, positive predictive 
power, negative predictive power, ROC 
curve, calibration curves etc. 
 
Yes No N/A 
Are the 
findings 
applicable 
Would the clinical prediction rule be 
reliable and results interpretable if used 
in assessing post concussion syndrome? 
Consider if your setting is too different 
from that of the study. 
 
Yes No N/A 
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Is the clinical prediction rule acceptable 
in assessing post concussion syndrome? 
Ease of use, availability, reasonable from 
a clinical point of view, cost 
Yes No N/A 
Would the results of the clinical 
prediction rule modify any decision 
about the management of a patient 
undergoing PCS assessment? 
Yes No N/A 
External & 
Internal 
Validity 
Were the subjects asked to participate 
in the study representative of the entire 
population from which they were 
recruited? 
The study must identify the source 
population for participants and describe 
how they were selected. Participants 
would be representative if they 
comprised the entire source population, 
an unselected sample of consecutive 
patients, or a random sample.  
 
Yes No 
Unable to 
determine 
Were study subjects in different groups 
recruited from the same population? 
For example, patients for all comparison 
groups should be selected from the same 
hospital. The question should be 
answered unable to determine for cohort 
and case control studies where there is 
no information concerning the source of 
patients included in the study.  
 
Yes No 
Unable to 
determine 
N/A 
Were study subjects in different groups 
recruited over the same time period? 
 
Yes No 
Unable to 
determine 
N/A 
Were subjects randomised into 
different groups? 
Studies which state that subjects were 
randomised should be answered yes 
except where method of randomisation 
would not ensure random allocation. For 
example alternate allocation would score 
no because it is predictable.  
 
Yes No 
Unable to 
determine 
N/A 
Power 
Did the study have sufficient power to 
detect a clinically important effect 
where the probability value for a 
difference being due to chance is less 
than 5%? 
Yes No 
Unable to 
determine 
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Lange 
et al. 
(2010) 
Iverson 
et al. 
(2010) 
Tsanadis 
et al. 
(2008) 
Van 
Dyke et 
al. 
(2010) 
Cooper 
et al. 
(2011) 
Greiffen-
stein et 
al. 
(2002) 
Parks 
et al. 
(2016) 
Lange 
et al. 
(2013) 
Sullivan 
et al. 
(2016) 
Is the hypothesis/aim/objective of the study clearly described?          
Are the main outcomes to be measured clearly described in the introduction or methods 
section? 
If the main outcomes are first mentioned in the Results section, the question should be answered 
No.  
 
         
Are the characteristics of the participants included in the study clearly described? 
In cohort studies and trials, inclusion and exclusion criteria should be given.  
 
         
Are the statistical methods used clearly described? 
 
 
         
Are the main findings of the study clearly described? 
Simple outcome data should be reported for all major findings so that the reader can check the 
major analyses and conclusions.  
 
         
Can the performance of the clinical prediction rule be calculated? 
Performance results can be presented as: sensitivity, specificity, positive predictive power, 
negative predictive power, ROC curve, calibration curves etc. 
 
N/A N/A N/A       
Appendix B 
Scoring sheet for evaluation tool  
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Would the clinical prediction rule be reliable and results interpretable if used in assessing 
post-concussion syndrome? 
Consider if your setting is too different from that of the study. 
 
N/A N/A N/A       
Is the clinical prediction rule acceptable in assessing post-concussion syndrome? 
Ease of use, availability, reasonable from a clinical point of view, cost 
N/A N/A N/A       
Would the results of the clinical prediction rule modify any decision about the management of 
a patient undergoing PCS assessment? 
N/A N/A N/A       
Were the subjects asked to participate in the study representative of the entire population 
from which they were recruited? 
The study must identify the source population for participants and describe how they were 
selected. Participants would be representative if they comprised the entire source population, an 
unselected sample of consecutive patients, or a random sample.  
 
      UTD   
Were study subjects in different groups recruited from the same population? 
For example, patients for all comparison groups should be selected from the same hospital. The 
question should be answered unable to determine for cohort and case control studies where 
there is no information concerning the source of patients included in the study.  
 N/A    UTD    
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Were study subjects in different groups recruited over the same time period? 
 
 
  UTD UTD UTD UTD    
Were subjects randomised into different groups? 
 
Studies which state that subjects were randomised should be answered yes except where method of 
randomisation would not ensure random allocation. For example alternate allocation would score 
no because it is predictable.  
 
N/A N/A N/A N/A N/A N/A    
Were the statistical tests used to assess the main outcomes appropriate? 
 
The statistical techniques used must be appropriate to the data. Keep in mind the possibility of type 
1 error. Were measures put in place to account for this (e.g. Bonferroni correction)? 
 
         
Did the study have sufficient power to detect a clinically important effect where the probability 
value for a difference being due to chance is less than 5%? 
UTD UTD UTD UTD UTD UTD UTD   
TOTAL SCORE 70% 56% 70% 67% 71% 57% 67% 87% 87% 
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Paper Two: Empirical Paper  
Validation of the Symptoms of Post-Concussion 
Syndrome Questionnaire as a Self-report Symptom 
Validity Test: A Simulation Study  
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Abstract 
Introduction – Symptoms of post-concussion syndrome (PCS) can be 
categorised into somatic, cognitive and emotional domains. Whilst specific 
neuropsychological tests can be used to determine cognitive disturbances as 
a result of PCS, there is a reliance on the use of self-report measures to 
record the presence and severity of other PCS symptoms, which can be 
subject to over report and exaggeration of symptoms. The Symptoms of 
Post-Concussion Syndrome questionnaire (SPCS) is a new measure 
designed to detect symptom exaggeration and over report in PCS. This study 
aimed to explore the utility of the SPCS as symptom validity test.  
Method – A simulation design was employed using control participants 
instructed to respond genuinely (n = 30), and participants instructed to 
malinger (n = 30). All participants completed a battery of measures that 
included established performance and symptom validity tests, alongside the 
new measure. Classification statistics were calculated to determine the 
effectiveness of the SPCS at distinguishing participants instructed to 
malinger from controls. Three different scoring methods were explored; a 
total SPCS score, total pseudo symptoms SPCS score, and a pseudo 
symptom endorsement frequency score.  
Results – Participants instructed to malinger had significantly higher scores 
on the SPCS compared with controls. An optimal cut off score of >25 was 
established for the ‘total SPCS score’ scoring method (sensitivity .90, 
specificity 1.00, positive predictive power = 100%, negative predictive power 
= 93.75%).     
Conclusion – The findings provide strong initial support for the use of the 
SPCS as a symptom validity measure. Its properties are promising, and 
classification statistics compare favourably with other established measures. 
However, further validation of the proposed cut off score with a clinical 
sample is required.     
 
Word count – 7,867 (inclusive of abstract – 273)  
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Validation of the Symptoms of Post-Concussion Syndrome (SPCS) 
Questionnaire as a Self-report Symptom Validity Test: A Simulation 
Study 
INTRODUCTION 
Following a mild head injury (MHI), some patients experience post-
concussion symptoms (such as headaches, irritability, anxiety, fatigue, 
memory difficulties and impaired concentration). Post-concussion syndrome 
(PCS) has been defined as a clinical state where 3 or more symptoms 
persist for more than 3 months (ICD-10 Version: 2016, World Health 
Organisation). Symptoms of PCS can be categorised into somatic, cognitive 
or emotional domains, as presented in Table 1. Neuropsychological tests 
measure deficits in cognitive functioning that can result from PCS. Alongside 
these tests there are various self-report measures that record and assess the 
development and severity of PCS symptoms.  
The detection of malingering or symptom exaggeration is an important 
component in the assessment of PCS. This may occur for a number of 
reasons, for example, consciously feigning or exaggerating illness to gain 
personal benefits and fulfilling “sick role” ideations, or to gain financial 
compensation (Binder & Rohling, 1996). It was estimated that 39% of 
litigants making MHI claims were suggestive of probable malingering 
(Mittenberg, Patton, Canyock, & Condit, 2002). A similar estimate of 40% 
was found by Larrabee (2003).  
Assessing the effort, or validity of performance, on cognitive tests is strongly 
encouraged when interpreting assessment results (Heilbronner et al., 2009). 
Clinical prediction rules can be used to estimate the probability of a specific 
outcome, and help clinicians to determine whether an individual is feigning or 
exaggerating symptoms (Toll, Janssen, Vergouwe and Moons, 2008). Tests 
of validity can provide clinicians with cut off scores to identify potential under 
performers and malingerers. Guidance on neuropsychological assessment 
published by the British Psychological Society (2009) states that measures of 
response validity should be given routinely as part of a clinical assessment of 
cognitive function. 
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Table 1 
Typical PCS symptoms (adapted from Snell, Macleod, and Anderson, 2016) 
Somatic Cognitive Psychological 
Fatigue Difficulty concentrating  Anxiety  
Headache  Memory problems  Depression  
Nausea  Slowed thinking  Irritability  
Vestibular symptoms Word finding difficulties  Emotional outbursts  
Light sensitivity  Difficulties with planning and 
organisation  
Personality changes  
Noise sensitivity    
Sleep disturbance    
Balance problems    
Tinnitus    
 
Following a need to clarify between self-report symptom validity measures 
and cognitive performance validity measures, it was recommended by 
Larabee (2012) that the terms performance validity test (PVTs) and symptom 
validity test (SVT) should be reported rather than terms such as “effort” or 
“response bias”. More specifically, PVTs are concerned with assessing the 
extent to which an individual’s performance on cognitive tests reflects their 
actual ability, so the accuracy or truthfulness of their cognitive profile 
according to neuropsychological measures. Whereas, SVTs are concerned 
with the extent to which an individual’s symptomatic complaints, as 
measured by self-report questionnaires, is reflective of their true experience 
of symptoms. They aim to detect the over report and exaggeration of 
symptoms.  
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Performance validity and symptom validity should be viewed as separate 
validity domains. Confirmatory factor analysis research carried out by Van 
Dyke, Millis, Axelrod and Hanks (2013) evaluated the factor structure 
underlying PVTs and SVTs, alongside measures of cognitive performance 
and symptom self-report not designed to measure validity. Out of the six 
models that were tested, a three-factor model, whereby cognitive 
performance, performance validity, and self-reported symptoms (including 
standard self-report measures and SVTs) were separate factors was the best 
fitting. This suggests that failure in one domain does not equate to failure in 
the other and that performance and symptom validity should be tested 
separately. Also of note was that SVTs and symptom report measures 
loaded on to the same factor. This may suggest that all self-report 
instruments measure symptom self-report and symptom validity on a 
continuum.  
Symptom validity in PCS can be assessed in a number of ways. The utility of 
self-report questionnaires originally designed to measure the severity of PCS 
symptoms have been investigated for use as SVTs. Tsanadis, Montoya, 
Hanks, Millis, Fichtenberg and Axelrod (2008) examined total scores of the 
Postconcussive Symptom Questionnaire (PCSQ; Lees-Haley, 1992) with a 
mild TBI and poor performance validity group in comparison with scores from 
a moderate to severe TBI group. The mild TBI group reported more 
symptoms with greater severity than the moderate to severe TBI group. It 
was argued that this was suggestive of symptom exaggeration and over 
reporting, and Tsanadis et al. (2008) used the results to question the validity 
of PCS diagnoses. A cut off score of >27 on the PCSQ was established by 
Van Dyke, Axelrod and Schutte (2010) to determine symptom validity in a 
military veteran sample.  
Other SVTs that have been validated for use with PCS include the Fake Bad 
Scale (FBS; Lees-Haley, English & Glenn, 1991), a 43-item self-report 
validity scale on the Minnesota Multiphasic Personality Inventory-2 (MMPI-2; 
Butcher, Dahlstrom, Graham, Tellegen, & Kaemmer, 1989) designed to 
detect the simulation of emotional distress in compensation seeking 
individuals. It was also used to detect the over report of symptoms in a 
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neurological sample. In a group of individuals with persistent PCS the FBS 
was found to be an effective measure of spurious symptom reporting 
(Greiffenstein, Baker, Gola, Donders and Miller, 2002) Some FBS items 
however, may have overlapped with true long-term outcomes in severe 
cerebral dysfunction and so specificity and false positive values for this 
measure are relatively poor in individuals with more severe presentations.  
The Structured Inventory of Malingered Symptomatology (SIMS; Widows and 
Smith, 2005) is a stand-alone SVT that has been researched in personal 
injury litigants due to TBI or exposure to trauma (Wisdom, Callahan & Shaw, 
2010) and with simulators of whiplash injury (Merten, Diederich, & Stevens, 
2008). Most recently Parks, Gfeller, Emmert and Lammert (2016) examined 
the validity of the SIMS in detecting feigned symptoms of PCS and PTSD. It 
was found that the SIMS total score produced the highest sensitivities for 
feigned PCS symptoms, supporting its use as an SVT screening measure in 
PCS. However, due to a lack of control condition in the design, no specificity 
or predictive values could be calculated, meaning that the extent to which the 
SIMS is able to discriminate individuals feigning PCS from those responding 
genuinely, is unknown. 
The five-item Mild Brain Injury Atypical Symptoms Scale (mBIAS; Cooper, 
Nelson, Armistead-Jehle, & Bowles, 2011) is an embedded measure that 
contains atypical symptoms not normally associated with PCS. Factor 
analysis revealed that the mBIAS items measure a unique dimension in 
symptom reporting and so responses should not be confounded by the 
presence of PCS. Cut off scores were presented to determine symptom 
exaggeration in individuals with mTBI, although any endorsement of items 
should be considered a marker for exaggeration. However, as this was not a 
known groups design and no established SVTs were administered alongside 
the mBIAS, Cooper and colleagues (2011) could not state with confidence 
whether over-reporting on the mBIAS could have been a function of 
conscious attempts to exaggerate symptoms, or if it was possible that the 
five items could have been endorsed in patients with co-occuring physical or 
sensory conditions. Lange and colleagues (Lange, Edmed, Sullivan, French, 
& Cooper, 2013) ran an analogue simulation study with the mBIAS, which 
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allowed for  greater internal validity and control, and found that it was 
effective at distinguishing between controls and participants feigning PCS. 
Two cut off scores were suggested, “highly probable exaggeration” and 
“possible exaggeration”, although sensitivity was low for the higher cut off 
value (.31).    
The Neurobehavioral Symptom Inventory Validity – 10 (NSI Validity-10; 
Vanderploeg, Cooper, Belanger, Donnell, Kennedy, Hopewell, & Scott, 2014) 
was found to produce very high classification statistics for distinguishing 
participants feigning PCS symptoms from controls in an analogue simulation 
design (Sullivan, Lange & Edmed, 2016). However, the suggested cut off 
scores were substantially lower than those found to be effective in previous 
research using a clinical TBI sample (Lange, Brickell, Lippa, & French, 2015; 
Vanderploeg, Cooper, Belanger, Donnell, Kennedy, Hopewell, & Scott, 
2014).  
Professional concern has been reported regarding information about 
validated tests being accessible through the Internet (Bauer & McCaffrey, 
2005). The coaching of litigants to detect and deceive performance and 
symptom validity tests has also been reported (Youngjohn, 1995; Wetter & 
Corrigan, 1995). This has resulted in PVTs and SVTs having a limited ‘shelf 
life’.  Providing a wide range of tests and the development of new tests may 
help to maintain test security (Bianchinni Mathias, & Greeve, 2001). 
Rationale, aims and hypotheses 
The development of new measures to detect symptom exaggeration and 
over reporting is important when assessing PCS, particularly in the context of 
a medico legal setting. Previous measures used to validate the self-report of 
PCS symptoms have been concerned with the endorsement of either 
genuine symptoms or atypical symptoms of PCS. The Symptoms of Post-
Concussion Syndrome (SPCS) questionnaire was developed by the research 
team as a new SVT for use in the assessment of PCS (see Appendix C). The 
SPCS is a 35-item self-report measure designed to detect the over report 
and exaggeration of PCS symptoms. It includes both genuine symptoms of 
PCS and atypical pseudo symptoms in order increase the likelihood of 
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detecting malingering. When developing a new measure, and validating new 
diagnostic and screening tools, evidence from analogue simulation designs 
should be collected (Rogers, 2008; Streiner, 2003). The American Academy 
of Clinical Neuropsychology Consensus Conference Statement on the 
Neuropsychological Assessment of Effort, Response Bias, and Malingering 
(Heilbronner, Sweet, Morgan, Larrabee, Millis & Conference Participants, 
2009) states that analogue simulation designs provide tight experimental 
control as well as being a practical and cost-effective method for examining 
‘‘proof of concept’’ for new tests. 
The purpose of this study was to evaluate the utility of the SPCS to detect 
the malingering of PCS symptoms using a simulation design. This will be 
established by determining whether the test has sufficient psychometric 
properties (sensitivity, specificity and predictive power values) to correctly 
identify instructed malingerers completing the measure, whilst also not 
incorrectly identifying control participants. Different scoring methods will be 
explored and reported. The psychometric properties and effectiveness of the 
SPCS will also be compared to an established SVT and two established 
PVTs.  
 
The following hypotheses were made: 
1) Participants who are instructed to malinger will have higher scores on 
all PVTs and SVTs in the test battery, including the SPCS, than 
controls who are instructed to respond genuinely. 
2)  The SPCS will be effective in discriminating between participants 
instructed to malinger and those participants instructed to respond 
genuinely. 
3) The SPCS will perform as well as established tests of performance 
and symptom validity at discriminating between participants instructed 
to malinger and those participants instructed to respond genuinely.  
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METHOD 
Design 
A Between subjects analogue simulation design was used. Control 
participants instructed to respond genuinely, and participants instructed to 
malinger were recruited from a neurologically healthy student population.  
Participants  
Recruitment of participants 
Neurologically healthy sample 
Participants were recruited from universities in the West Midlands via a 
recruitment email notification that was disseminated to all students via faculty 
and/or school leads (see Appendix D). Potential participants expressed their 
interest to the lead researcher and were sent an information sheet containing 
further details about the research project (see Appendices E & F) and 
participants were given the opportunity to book an available time slot to take 
part. Information concerning participants’ sex, age, and years of education 
was collected. Participants were asked if they had any current or historical 
neurological condition(s) or if they had suffered a current or historical head 
injury (including a history of concussion). Any participants who responded 
positively to either of the two screening questions were not included in the 
research.  
The following inclusion/exclusion criteria applied to the neurologically healthy 
sample: 
Inclusion criteria: 
1. Individuals must be aged 18+  
2. Individuals must be fluent in English language 
Exclusion criteria: 
1. Individuals with any historical or current neurological condition, 
including traumatic brain injury or previous concussion. 
2. Individuals with a diagnosis of a learning disability.  
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Clinical sample: 
It was originally intended for a clinical sample of individuals with mild TBI, 
who fit the criteria for a diagnosis of PCS, to also be included in this research 
project. However, constraints on the inclusion/exclusion criteria (as agreed 
by the NHS REC) prohibited individuals who were seeking compensation or 
were receiving benefits, which would have significantly reduced the number 
of potential participants. Furthermore, clinicians who were approached to 
assist with recruitment to the study shared that due to funding pressures in 
NHS neuro-rehabilitation services, very few individuals with mild TBI were 
picked up in comparison to moderate-severe TBI. An identified specialist 
Accident & Emergency Neuropsychology partnership service failed to 
respond to requests to participate.   
The following inclusion/exclusion criteria applied to potential participants in 
the clinical sample:  
Inclusion criteria: 
1. Individuals must be aged 18+  
2. Individuals must have a traumatic brain injury (TBI) – sub-acute to 
chronic phase of recovery (determined by the clinician working with 
the individual) receiving community based rehabilitation (3 months 
post injury)   
3. Individuals must be fluent in English language  
 
Exclusion criteria: 
1. Individuals seeking or intending to seek compensation or disability 
benefits in relation to their head injury. 
2. Individuals that are in the acute phase of recovery (determined by the 
clinician working with the individual) 
3. Individuals that have a co-morbid neurological condition (determined 
by the clinician working with the individual) 
4. Individuals that had a pre-morbid learning disability 
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Participant demographics: 
60 neurologically healthy students from universities in the West Midlands 
were recruited to take part in the study. Demographic information for 
participants was as follows: 71.67% female, with a mean age of 30.67 (SD 
10.79), and 17.45 (SD 2.78) years of education. All participants were fluent in 
English language and did not have any historical or current neurological 
condition, including TBI or previous concussion.  
Procedure 
Neurologically healthy participants were randomly allocated to either the 
control, or instructed to malinger group. Random assignment of participants 
was conducted by use of a random number generator computer programme. 
All participants were informed that the study was investigating methods of 
assessment in post-concussion syndrome. Participants in the instructed to 
malinger condition were provided with a vignette (see Appendix J) detailing 
their role in the study. The vignette involved a fictional scenario in which 
participants were to imagine that they had been involved in a car accident. 
They were told that they lost consciousness for about 15 minutes and awoke 
spontaneously without being woken by others. Over time they feel normal 
again and were unharmed by the accident. Due to the accident, however, 
they were involved in a lawsuit against the driver of the other car and are 
required to undergo psychometric testing. Participants were informed that if 
they were found to have suffered injuries as a result of the accident they 
would receive a large settlement. The vignette instructs participants to fake 
the symptoms of a brain injury in order to gain compensation. Control group 
participants were instructed to respond honestly. All participants were then 
administered a battery of assessment measures (detailed below).  
Following completion of the test battery, participants received a debrief in 
which they were informed of the actual purpose of the study (see debrief 
statement in Appendix I). Passive deception was used concerning the 
established performance and symptom validity tests in order to preserve their 
function of detecting symptom exaggeration and over reporting.   
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Measures 
The Hospital Anxiety and Depression Scale (HADS; Zigmond and Snaith, 
1983) is a 14-item self-report questionnaire designed to determine levels of 
anxiety and depression. Each item on the measure is scored from 0-3. 
Seven of the items relate to anxiety and seven to depression. Two separate 
scores are generated simultaneously of between 0-21 for both anxiety and 
depression.  
The Test of Premorbid Functioning (TOPF-UK; Wechsler, 2011) is a reading 
test composed of a list of 70 words that have atypical grapheme to phoneme 
translations. It is designed to estimate premorbid intelligence and memory 
abilities. The TOPF-UK can be described as a “hold test”, in that it relies on 
abilities thought to be unaffected by decline associated with neurological 
damage. Examinees are presented with the word list and instructed to 
pronounce each word aloud. Each correct pronunciation is awarded a score 
of one, and the test is discontinued after five incorrect pronunciations.   
The Test of Memory Malingering (TOMM; Tombaugh, 1996) is a test of 
performance validity that is commonly used by neuropsychologists (Sharland 
& Gfeller, 2007). It employs a forced-choice recognition paradigm using line 
drawings of 50 common objects. Examinees are presented each drawing for 
three seconds. The test phase of the measure then involves participants 
correctly identifying the drawing they had been shown previously when it is 
presented alongside a distractor drawing. The examiner provides verbal 
feedback and corrects the participant if they make an incorrect choice. The 
trial serves a dual function as a test of performance validity and also as an 
additional learning trial. Participants are then shown the same 50 line 
drawings followed by another test phase. After approximately 15 minutes, 
participants are presented with a retention test in which the 50 line drawings 
are again presented alongside more distractor drawings. Total scores from 
each trial are obtained from the number of original line drawings that were 
correctly identified. Cut off scores are then utilised to determine the likelihood 
that an individual is malingering.  
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The Word Memory Test oral form (WMT; Green & Astner, 1995) is a test of 
performance validity that detects sub optimal performance in relation to an 
individual’s immediate and delayed memory performance. Participants are 
read a list of 20 word pairs, after the list has been read through twice, there 
is an immediate recognition trial. Participants are tested using a forced-
choice recognition paradigm whereby they are read new word pairs 
containing only one of the words belonging to the original list and they are 
asked to select the word from the original list. A delayed recognition test then 
follows 30 minutes later containing different foil words. Scoring of the WMT 
involves a consistency calculation from the responses on the immediate and 
delayed recognition tests. The WMT also includes a multiple choice task, 
where participants are given the first word in each word pair and must select 
the correct word to match it from eight options. A paired associates task 
involves the examiner telling the participant the first word and asking for the 
second word in each word pair. Delayed free recall requires participants to 
state as many words as possible from the original list in any order. Long 
delayed free recall is the same task but after a further 20 minute delay. 
Scores below 82.5% on the immediate recognition, delayed recognition and 
consistency indices are indicative of invalid performance.   
The Self-Report Symptom Inventory (SRSI; Merten, Merckelbach, Giger, & 
Stevens, 2016) is a 107 item self-report SVT that combines genuine clinical 
and pseudo symptoms scales. It contains the following five subscales 
covering genuine commonly endorsed symptoms: cognitive, depressive, 
pain, non-specific somatic, and PTSD/anxiety. The pseudo symptoms scales 
concern cognitive/memory, neurological motor, neurological sensory, pain, 
anxiety/depression. All items are presented in a true/false format and 
participants are required to respond to each statement. Over-reporting of 
symptoms is gauged in two ways: by looking at the sum scores of endorsed 
pseudo symptoms and by inspecting the ratio between the number of 
endorsed genuine symptoms and that of endorsed pseudo symptoms.  
The Symptoms of Post-Concussion Syndrome questionnaire (SPCS) is a 35 
item self-report questionnaire (see Appendix C). Items include 20 common 
symptoms of PCS as well as 15 pseudo symptoms. The symptom items 
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were selected and developed from the over reporting scales in the Minnesota 
Multiphasic Personality Inventory – Second edition (MMPI-2; Butcher et al., 
1989) with the support of a Consultant Clinical Neuropsychologist with 
extensive experience of working with TBI presentations. Pseudo symptoms 
were selected as bizarre, atypical or uncommon complaints that in the eyes 
of laypersons, appear to belong to PCS. Participants report the severity of 
symptoms by rating the extent that the symptoms have disturbed them over 
the last two weeks on a four-point Likert scale (0 = not experienced, 1 = 
minor nuisance, 2 = moderate problem, and 3 = severe problem).  A total 
score is obtained by summing the rating for all 35 items. A separate pseudo 
symptoms score can also be obtained by summing the endorsement of the 
15 pseudo symptoms items. A pseudo symptoms frequency score can also 
be calculated by totalling the frequency of endorsed pseudo symptoms 
items. This study will investigate which of these scoring methods produces 
the more precise sensitivity, specificity and predictive values, and will report 
their respective cut off scores.   
 
Statistical analysis 
To address the hypotheses, different statistical analyses were performed.  
Comparisons of scores on the performance and symptom validity tests were 
made between the control and instructed to malinger groups. The 
psychometric properties of the SPCS were established by running a 
Receiver Operating Characteristic (ROC) curve analysis. ROC curves are 
often encountered in research papers that evaluate a new application of a 
clinical test. A ROC curve analysis provides information concerning a test’s 
sensitivity, specificity and predictive power. ROC curve analysis was used to 
graphically represent how changes in cut-off values for the total SPCS score 
and the pseudo symptoms SPCS score impacted the resulting sensitivity and 
specificity values. Sensitivity indicates how often the test will be positive in 
the existence of over-reporting of symptoms. Specificity indicates how often 
the test will be negative in those responding truthfully.  Clinical prediction 
rules should also have good negative predictive power (NPP) and positive 
predictive power (PPP), which refer to the level of confidence in the accuracy 
of a negative (pass) and positive (fail) result respectively. NPP and PPP 
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were calculated using a base rate of malingering set at 40%, in keeping with 
the findings reported by Larrabee (2003) and Mittenberg et al. (2012). To 
reduce the likelihood of false positives, only cut-off scores that produced 
specificity figures of above .95 were considered acceptable.  
 
Sample size calculation 
A sample size of approximately 60 participants (30 analogue malingerers 
and 30 controls) would afford a precision of 0.81 standardised units at a 
statistical power of 0.80. As participants in the control group condition are 
expected to perform at near ceiling levels on performance and symptom 
validity tests with relatively small standard deviations, a statistical power of 
0.80 and a precision of 0.81 would be adequate to test between group 
differences. More specifically, in order to determine the standard error value, 
a confidence interval calculation was performed for a sample size of 60. This 
produced a standard error of 0.035 (degrees of freedom = 58).   
 
Ethical and regulatory considerations 
Risk and Management of risk 
Prior to taking part, participants were provided with participant information 
sheets (see Appendices E & F) stating that there were no anticipated major 
physical or emotional risks involved in taking part in the study. However, it 
was possible that participants may have been aware that they were unable to 
answer all of the questions or complete all of the tasks and may have felt 
despondent because they felt as though they were failing.  Participants were 
given the option of not providing an answer to the questions that they 
deemed inappropriate, or difficult to answer, or for which they preferred not 
to give an answer. Participants were warned about this prior to engaging in 
the study and were informed that different people perform differently on all 
aspects of the tests.  At the end of the session there was time set aside to 
allow for participants to discuss their experiences and ask any questions.  
It is possible that participants may have felt uncomfortable with the use of 
passive deception with regards to the use of performance and symptom 
validity test measures. Participants were fully debriefed immediately after 
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completing the test battery, and all participants were given a debrief sheet 
(see Appendix I). Participants were given the opportunity to discuss the study 
with the researcher and were reminded of their right withdraw from the study 
should they wish to do so. Participants were also given the contact details of 
the researcher and research supervisor should they wish to discuss the 
study further. Participants were also given an appropriate contact within their 
university in case of any adverse effects on their mental wellbeing as a result 
of their participation or exposure to the questions.    
Consent: 
Informed consent was obtained prior to participants engaging in the study 
(see consent form in Appendices G & H). The study did require the use of 
passive deception in relation to the function of the performance validity and 
symptom validity tests included in the test battery. Participants were fully 
debriefed following completion of the study and informed of the true purpose 
of the study and reminded of their right to withdraw their data up until the 
point of data analysis (three weeks after their participation).  
Ethical approval: 
The research proposal for this study was subject to an independent peer 
review at Staffordshire University and was approved on 03/05/16 (see 
Appendix K). The study was granted ethical approval from the West 
Midlands – Edgbaston Research Ethics Committee on the 08/09/16 (see 
Appendix L for a copy of the favourable opinion letter), and Health Research 
Authority (HRA) approval was granted on 05/12/16 (see Appendix M).  
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RESULTS 
Demographic variables 
The control group was made up of 73.3% female and 26.7% male 
participants with an average age of 31.53 (SD 11.54) and 16.83 (SD 2.57) 
years of education. The instructed to malinger group was composed of 
70.0% females and 30.0% male participants with an average age of 29.8 (SD 
10.12) and 18.07 (SD 2.89) years of education. Non-parametric between 
group comparisons revealed that there were no significant differences found 
for sex (χ² (1, N = 60) = .082, p = .774), age (U = 390, p = .374) or years of 
education (U = 562, p = .093) between the control and instructed to malinger 
group.   
Premorbid functioning, anxiety, and depression scores 
Descriptive statistics, group comparisons (nonparametric due to non-normal 
distributions) and Cohen’s effect sizes are presented in Table 2. Statistically 
significant differences were observed for premorbid functioning scores (U = 
297, p =. 024), as measured by the TOPF-UK, and anxiety scores (U = 
808.5, p = <.001) and depression scores (U = 839.5, p = <.001), as 
measured by the HADS. These differences were not seen to be valid 
however, as the analogue malingerers were likely to have purposely 
performed with sub optimal performance on the TOPF-UK and over-reported 
symptoms of anxiety and depression in their role as malingerers on the 
HADS.  
As statistically significant differences in TOPF-UK and HADS scores were 
observed between the control and instructed to malinger groups, correlations 
examining the relationship of TOPF-UK and HADS scores with SPCS scores 
were performed on control group and instructed to malinger group data 
separately, rather than as a whole data set. 
Kendall’s tau-b rank correlation co-efficient was performed to examine the 
relationship between SPCS scores and TOPF-UK premorbid functioning, 
HADS anxiety and HADS depression scores within the control group. There 
was a positive statistically significant relationship between the SPCS scores 
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and HADS anxiety scores; τ (28) = .51, p = 0.01., and HADS depression 
scores; τ (28) = .57, p = 0.01. No significant relationship was found between 
the SPCS scores and TOPF-UK premorbid functioning scores; τ (28) = -.23, 
p = 0.10. 
Correlations performed with the instructed to malinger group scores revealed 
positive statistically significant relationships of the HADS anxiety scores; τ 
(28) = -.50, p = 0.01, and HADS depression scores; τ (28) = -.50, p = 0.05 
with the SPCS scores. No significant relationship was found between 
premorbid functioning scores and SPCS scores; τ (28) = -.21, p = 0.11. 
Table 2  
Descriptive statistics and group comparisons for the TOPF-UK and HADS by 
group 
 Control Instructed to malinger   
Measure M SD M SD P Cohen’s  
effect size (d)  
Total scores        
TOPF-UK  53.77 9.51 45.77 11.94 .024 .76 
HADS anxiety  5.37 2.83 13.27 4.68 <.001 2.10 
HADS depression 1.30 1.58 10.30 5.43 <.001 2.57 
Note. N = 60; controls (n = 30), instructed to malinger (n = 30). Cohen’s effect sizes = small 
(0.2), medium (0.5), large (0.8). TOPF-UK = Test of Premorbid Functioning; HADS = 
Hospital Anxiety and Depression Scale.  
Clinical scales 
To explore the effect of experimental condition on the results of the 
established PVT and SVT measures a series of comparisons were 
performed on the TOMM, WMT and SRSI outcome results as the dependent 
variable, and the experimental condition (control or instructed to malinger 
group) as the independent variable. There were significant main effects 
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(using Kruskal-Wallis H tests) for the pass and fail frequencies on the 
TOMM, WMT, and SRSI measures (all p < .001), as presented in Table 3.  
Contingency frequencies of pass/fail rates on the TOMM, WMT and SRSI 
measures between the control and instructed to malinger groups are 
presented in Table 4.  
Table 3 
Kruskal-Wallis H findings for TOMM, WMT, and SRSI  
Measure Chi square  Df p 
TOMM 34.16 1 <.001 
WMT 39.33 1 <.001 
SRSI 39.33 1 <.001 
Note. N = 60; control (n = 30), instructed to malinger (n = 30). All p = <.001. TOMM = Test of 
Memory Malingering; WMT = Word Memory Test; SRSI = Self-Report Symptom Inventory.  
Table 4 
Contingency frequencies and percentages for the TOMM, WMT and SRSI 
pass/fail frequencies by group 
Measure  Control Instructed to 
malinger 
Total 
TOMM Pass 30 (100%) 8 (26.7%) 38 (63.3%) 
Fail 0 (0%) 22 (73.3%) 22 (36.7%) 
WMT Pass 30 (100%) 6 (20.0%) 36 (60.0%) 
Fail  0 (0%) 24 (80.0%) 24 (40.0%) 
SRSI Pass 30 (100%) 6 (20.0%) 36 (60.0%) 
Fail  0 (0%) 24 (80.0%) 24 (40.0%) 
Note. N = 60; control (n = 30), instructed to malinger (n = 30). TOMM = Test of Memory 
Malingering; WMT = Word Memory Test; SRSI = Self-Report Symptom Inventory.  
The sensitivity, specificity and predictive values were calculated for the 
TOMM, WMT and SRSI using their respective cut off values with base rate 
set at 40%. The TOMM had a sensitivity value of .73, a specificity value of 
1.00, PPP of 100% and NPP of 85%. The WMT had a sensitivity value of 
.80, a specificity value of 1.00, PPP of 100% and NPP of 88%. The SRSI had 
a sensitivity of .80, a specificity value of 1.00, PPP of 100% and NPP of 88%.  
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SPCS symptom reporting  
The effect of experimental condition on the SPCS symptom reporting was 
explored with a series of non-parametric between-groups comparisons 
(using Kruskall-Wallis H). The dependent variable for this comparison was 
one of the three SPCS scoring methods (total SPCS score, total pseudo 
symptom SPCS score, or pseudo symptom endorsement frequency score). 
The independent variable was the experimental condition. Descriptive 
statistics, group comparisons and effect sizes for the pseudo symptoms total 
score and frequency of pseudo symptom item endorsement are presented in 
Table 6. There were significant main effects for the total scores on the SPCS 
(X = 42.36, p = <.001) with an effect size of 3.03, the pseudo symptoms 
SPCS total scores (X = 30.87, p = <.001) with an effect size of 2.05, and the 
pseudo symptom endorsement frequency score (X = 29.65, p = <0.01) with 
an effect size of 2.17.  
Comparisons were also made for each of the pseudo symptom items. There 
were significant main effects found in 14 of the 15 pseudo symptoms 
included in the SPCS items and these are presented in Table 7.  
Table 6 
Descriptive statistics, group comparisons and effect sizes for SPCS index 
scores 
 Control Instructed to malinger   
Index 
M SD M SD P Cohen’s  
effect size (d)  
        
Total SPCS  9.57 6.31 51.87 21.65 <.001 3.03 
Total pseudo symptoms  1.87 2.56 15.17 10.40 <.001 2.05 
Pseudo symptoms freq. 1.57 2.05 9.13 4.90 <.001 2.17 
Note. N = 60; controls (n = 30), Instructed to malinger (n = 30). Cohen’s effect sizes = small 
(0.2), medium (0.5), large (0.8). SPCS = Symptoms of Post-Concussion Syndrome 
questionnaire.   
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Table 7 
Between groups comparison statistics (Kruskal-Wallis H) of pseudo symptom 
items.   
  
Pseudo Symptom items  Test 
statistic  
P 
PS1 - Difficulty remembering personal details 33.62 <.001 
PS2 - Lump in the throat 
 
1.90   .169 
PS3 - Sweating all over 
 
20.25 <.001 
PS4 - Feeling hot all over 
 
10.32   .001 
PS5 - Reduced sensitivity in fingers and toes 15.67 <.001 
PS6 - Legs feeling weak  
 
15.70 <.001 
PS7 - Tingling sensation at the tip of the nose and/or lips 17.70 <.001 
PS8 -Occasional numbness in hands and feet 15.24 <.001 
PS9 - Hot or cold sensations on the skin 5.79   .016 
PS10 - Mouth becoming dry  12.79 <.001 
PS11 - Everything tastes the same 19.26 <.001 
PS12 - Frequent pins and needles 25.10 <.001 
PS13 - Fainting spells 
  
18.20 <.001 
PS14 - Difficulty remembering the gist of conversations  31.05 <.001 
PS15 - Difficulty recalling information about my 
childhood 
29.55 <.001 
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Utility of the SPCS  
To determine the utility of the SPCS as a tool to identify malingerers from 
controls, diagnostic efficiency statistics (sensitivity, specificity, PPP, and 
NPP) were calculated for the total SPCS scores, pseudo symptom SPCS 
scores, and pseudo symptom endorsement frequency scores.  
ROC curve analysis of the total SPCS scores provided an area under the 
curve (AUC) of .989, with a standard error measurement of .009 and the 
95% confidence interval range from .972 to 1.00 suggesting highly accurate 
classification. Different cut off scores with their respective sensitivity and 
specificity values are presented in Table 6. Optimal cut-off scores were 
identified by examination and exploration of sensitivity, specificity and 
predictive power values. A cut score of >22 produced .93 sensitivity, .90 
specificity, 95.07% NPP, and 86.11% PPP. However, to prevent false 
positive findings, specificity was set at 1.00, and a cut-off score of >25 was 
established which produced .90 sensitivity and 93.75% NPP and 100% PPP.  
ROC curve analysis of the pseudo symptoms total score revealed an AUC of 
.914 with a standard error measurement of .40, and a confidence interval 
range of .835 to .992. Different cut-off scores with their respective sensitivity 
and specificity values are presented in Table 7. Optimal cut-off scores were 
identified by examination and exploration of sensitivity, specificity and 
predictive power values. Cut-off scores are presented in Table 6. A cut-off 
score of >7 produced .73 sensitivity, .96 specificity, 84.42% NPP, and 
92.24% PPP. 
ROC curve analysis of the frequency of pseudo symptoms score revealed an 
AUC of .906 with a standard error measurement of .041, and a confidence 
interval range from .825 to .986. Different cut-off scores with their respective 
sensitivity and specificity values are presented in Table 8. Optimal cut-off 
scores were identified by examination and exploration of sensitivity, 
specificity and predictive power values. A cut-off score of >7 produced .67 
sensitivity, 1.00 specificity, 81.97% NPP, and 100% PPP. 
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Table 6 
Sensitivity and specificity values for different cut offs for the SPCS total score 
method on the SPCS measure 
Cut off score Sensitivity  1-Specificity  
>1 1.000 .967 
>2 1.000 .900 
>3 1.000 .867 
>4 1.000 .833 
>5 1.000 .733 
>6 1.000 .700 
>7 1.000 .567 
>8 1.000 .467 
>9 1.000 .400 
>10 1.000 .300 
>12 1.000 .233 
>13 1.000 .200 
>14 1.000 .167 
>16 1.000 .133 
>17 .967 .133 
>19 .933 .133 
>21 .933 .100 
>22 .933 .067 
>23 .900 .067 
>25 .900 .000 
>28 .867 .000 
>29 .833 .000 
>32 .800 .000 
>36 .767 .000 
>38 .667 .000 
>41 .633 .000 
>45 .600 .000 
>46 .567 .000 
>48 .533 .000 
>51 .467 .000 
>56 .400 .000 
>59 .333 .000 
>63 .267 .000 
>67 .233 .000 
>70 .200 .000 
>73 .167 .000 
>81 .133 .000 
>88 .100 .000 
>92 .033 .000 
>95 .000 .000 
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Table 7 
Sensitivity and specificity values for different cut offs for the total pseudo 
symptoms scoring method on the SPCS measure 
  Cut off score  Sensitivity  1-Specificity  
.50 .933 .567 
1.50 .933 .367 
2.50 .900 .300 
3.50 .900 .167 
4.50 .833 .133 
6.00 .767 .133 
7.50 .733 .033 
8.50 .700 .033 
9.50 .700 .000 
10.50 .667 .000 
11.50 .633 .000 
12.50 .567 .000 
14.00 .533 .000 
15.50 .467 .000 
16.50 .400 .000 
17.50 .367 .000 
18.50 .333 .000 
19.50 .300 .000 
21.00 .200 .000 
22.50 .167 .000 
27.00 .133 .000 
32.50 .100 .000 
35.00 .067 .000 
38.00 .033 .000 
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Table 8 
Sensitivity and specificity values for different cut offs for the pseudo 
symptoms endorsement frequency scoring method on the SPCS measure 
  
Cut off score  Sensitivity  1-Specificity  
.50 .933 .567 
1.50 .933 .367 
2.50 .900 .233 
3.50 .800 .167 
4.50 .733 .100 
5.50 .733 .067 
6.50 .700 .067 
7.50 .667 .000 
8.50 .567 .000 
9.50 .533 .000 
10.50 .500 .000 
11.50 .400 .000 
12.50 .333 .000 
13.50 .233 .000 
14.50 .167 .000 
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DISCUSSION 
This study aimed to examine the utility of a new measure, the SPCS, using 
data from an analogue simulation study. More specifically, this study 
explored the ability of the SPCS to discriminate between controls and 
participants instructed to malinger. The hypotheses were three-fold. Firstly, 
participants who are instructed to malinger would have higher scores on all 
PVTs and SVTs in the test battery, including the SPCS, than controls who 
are instructed to respond genuinely. Second, the SPCS would be effective in 
discriminating between participants instructed to malinger and those 
participants instructed to respond genuinely. Finally, the SPCS would 
perform as well as established tests of performance and symptom validity at 
discriminating between participants instructed to malinger and those 
participants instructed to respond genuinely. Overall, the main findings from 
this study supported these hypotheses.  
As predicted in the first hypothesis, participants who were instructed to 
malinger had significantly higher scores (or test failure rates) on the TOMM, 
WMT, SRSI and SPCS. Main effects were found for three different SPCS 
index scores that were extracted from the data (total SPCS score, total 
pseudo symptom SPCS score, and pseudo symptom endorsement 
frequency score). Significant correlations were found between the SPCS 
total scores and ratings of anxiety and depression, indicating a positive 
relationship. No significant correlation was found however, between SPCS 
scores and premorbid functioning, indicating that intellectual and memory 
abilities did not bear any relationship with SPCS responses.   
As part of the investigation into of the utility of the SPCS measure, different 
scoring methods (total SPCS score, total pseudo symptom SPCS score, and 
pseudo symptom endorsement frequency score) were explored. The total 
SPCS score was calculated from summing all of the item responses. This 
scoring method produced cut-off values with the most favourable diagnostic 
efficiency statistics. A cut-off score of >25 was selected to identify “probable 
malingering” which produced high sensitivity (.90) and specificity (1.00). In 
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comparison the identified cut-off values for the total pseudo symptom SPCS 
score and pseudo symptom endorsement frequency scoring methods 
produced lower classification statistics of .73 and .67 sensitivity, and .96 and 
1.00 specificity respectively. It is therefore, recommended that the total 
SPCS scoring method and cut-off value of >25 is used to distinguish 
malingerers from genuine responders as this produced the highest sensitivity 
value when specificity was set at >.95.  However, a score that exceeds either 
of the two cut-offs for the pseudo symptom scoring methods should be 
considered a “red flag” for possible symptom exaggeration.  
In comparison to other performance and symptom validity tests included in 
this study, classification statistics revealed that the total SPCS score was 
more effective at determining malingering of PCS symptoms from genuine 
responders. Thus suggesting it is a very effective SVT measure. It is 
important to acknowledge, however, that the SPCS cut off score was 
established with neurologically intact individuals, and the sensitivity of the 
measure may reduce with a clinical TBI population.  
In this study it was found that the WMT, SRSI and SPCS measures were 
more effective than the TOMM at discriminating malingerers from control 
participants, yet, it was reported from a survey of practicing 
Neuropsychologists, that the TOMM is one of the most frequently used 
validity measures (Sharland & Gfeller, 2007). Previous concerns have been 
expressed about the sensitivity of the TOMM, and reports have been made 
of high false negative rates (Bauer, O’Bryant, Lynch, McCaffrey, & Fisher, 
2007; DenBoer & Hall, 2007; Gervais, Rohling, Green & Ford, 2004; Tan, 
Slick, Strauss, & Hultsch, 2002; van Hout, Schmand, Wekking, Hageman, & 
Deelman, 2003).  
As the SPCS is a new SVT there is no previous research specifically 
concerning its effectiveness as a measure to directly compare the findings 
from this study with. Investigative studies of other SVT measures however, 
indicate that the SPCS shows promising preliminary findings as a new 
measure. Classification statistics reported in this study compare favourably 
with those reported in previous literature. Research using an analogue 
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simulation to investigate the utility of the mBIAS (Lange et al, 2013), a 
measure which also involved ratings of pseudo symptoms to detect 
malingering, reported a “possible exaggeration” cut-off score that provided a 
sensitivity value of .62, specificity of .88, PPP of 73% and NPP of 81% (with 
base rate set at 35%) for the feign PCS condition. When specificity was set 
at 1.0, a “probable exaggeration” cut-off score provided a sensitivity value of 
just .31, PPP of 100% and NPP of 73% (with base rate set at 35%) for the 
feign PCS condition. Further findings on the NSI Validity-10 revealed more 
efficient classification statistics for the feign PCS condition with a “probable 
exaggeration” cut off providing a sensitivity value of .97, specificity of .96, 
PPP of 93%, and NPP of 98% (with base rate set at 35%) (Sullivan et al., 
2016). Parks and colleagues (2016) reported that the SIMS had a sensitivity 
value of .89 when detecting feigned PCS symptoms, other classification 
statistics were not available. Research into PCS SVTs with clinical samples 
reported similar findings regarding classification statistics. Van Dyke and 
colleagues (2010) reported findings for the PCSQ tested for its use as an 
SVT. Sensitivity was found to be somewhat low for the suggested cut-off 
score (.36), whilst specificity was .94, PPP was 69.2%, and NPP was 80.5%. 
The optimal cut-off score for the mBIAS proposed in Cooper et al. (2011) 
produced better sensitivity of .94, and specificity of .92, PPP was 83%, and 
NPP was 97% (with base rate set at 30%).   
Clinical implications 
 The SPCS has been found to be an effective measure of distinguishing 
participants who were instructed to malinger from controls. The measure was 
also found to be more effective than existing PVT and SVT measures in this 
study. Clinically, the SPCS may be of benefit to Neuropsychologists working 
in mTBI services to detect potential cases of symptom exaggeration and over 
reporting. The SPCS can be completed in less than 5 minutes, and it is quick 
and straight forward to score and interpret which may be advantageous over 
other longer self-report measures, particularly in busy services where 
screening sessions may be time pressured. A patient’s neuropsychological 
profile should not be discounted upon the results of a single SVT, however, 
when used as a screening tool, the SPCS may be used as an indicator of 
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symptom exaggeration and prompt clinicians to be cautious about the 
interpretation of other self-report measures. A clinical validation of the 
recommended cut-off scores is required however, in order to provide 
confidence for use in a clinical setting.     
 
Limitations 
A limitation in this research project was the lack of a clinical sample. 
Although a simulation design provides the most control for internal validity, it 
could be argued that analogue simulation designs lack ecological validity. 
The initial design for this study involved recruiting a clinical sample alongside 
neurologically healthy subjects, which may have resolved potential issues 
with generalisability. It is possible that further validation with a clinical 
population may reveal that the cut-off scores suggested in this paper need to 
be adjusted, and this should be explored in future research. Sullivan, Lange 
and Edmed (2016) found that an investigation into the utility of the NSI 
validity-10 using an analogue simulation design produced lower cut-off 
scores than was previously found in research involving clinical samples 
(Lange, Brickell, Lippa, & French, 2015; Vanderploeg, Cooper, Belanger, 
Donnell, Kennedy, Hopewell, & Scott, 2014). It is argued that the differences 
may be due to the use of different measures to define groups. It is worth 
noting that several studies have reported that simulators instructed to 
malinger may not significantly differ from clinical populations seeking 
secondary gain (Meyers, 2007; Mittenberg, Theroux-Fichera, Zielinski, & 
Heilbronner, 1995; Rohling, Meyers, & Millis, 2003).  
Another limitation of this study is that there was no questionnaire measure 
confirming that exaggeration was induced in the instructed to malinger group 
condition. There is a possibility that some participants misunderstood 
instructions given to them and did not fake the symptoms of a brain injury. 
This may have impacted the findings in the study, however, this is unlikely as 
a high sensitivity value (.90) was calculated.  
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CONCLUSION 
In summary, this study provided preliminary support for, the SPCS, a new 
measure of symptom validity. Three different scoring methods were explored 
to identify the most effective way of utilising data from the measure. The total 
SPCS score was found to be most effective. However, a score above the cut 
off values of the pseudo symptoms total score and frequency score should 
also be considered a “red flag”. The SPCS showed promising preliminary 
results for use as a population screening tool. It allows for a rapid 
assessment of symptom validity which is beneficial to Neuropsychologists 
operating within services that are highly time pressured. There is a need for 
validation with a clinical sample, however, and this is a recommendation for 
future research. It is worth acknowledging that a patient’s neuropsychological 
profile should not be discounted upon the results of a single SVT, and the 
SPCS is not intended to be used for purely diagnostic purposes. Although 
SVTs and PVTs have an essential role in determining valid responding, 
ultimately, it is the role of the expert clinician to make any attributions of 
symptom exaggeration or malingering (Lockhart, 2015).  
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Appendix O 
SPSS Output: Demographic group differences  
 
Report 
Group Age 
Years of 
education 
Control Mean 31.53 16.83 
N 30 30 
Std. Deviation 11.539 2.574 
Malinger Mean 29.80 18.07 
N 30 30 
Std. Deviation 10.121 2.888 
Total Mean 30.67 17.45 
N 60 60 
Std. Deviation 10.797 2.783 
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Appendix P 
SPSS Output: Premorbid functioning, anxiety, and depression comparisons  
 
Report 
Group TOPF HADS anxiety 
HADS 
depression 
Control Mean 53.07 5.37 1.30 
N 30 30 30 
Std. Deviation 9.505 2.834 1.579 
Malinger Mean 45.77 13.27 10.30 
N 30 30 30 
Std. Deviation 11.936 4.675 5.428 
Total Mean 49.42 9.32 5.80 
N 60 60 60 
Std. Deviation 11.313 5.528 6.025 
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Appendix Q 
SPSS Output: Within group premorbid functioning, anxiety, and depression 
correlations (malingering group) 
 
 
Correlations 
 topf anxiety depression spsq 
Kendall's tau_b topf Correlation Coefficient 1.000 -.163 -.160 -.212 
Sig. (2-tailed) . .221 .229 .107 
N 30 30 30 30 
anxiety Correlation Coefficient -.163 1.000 .599
**
 .496
**
 
Sig. (2-tailed) .221 . .000 .000 
N 30 30 30 30 
depression Correlation Coefficient -.160 .599
**
 1.000 .504
**
 
Sig. (2-tailed) .229 .000 . .000 
N 30 30 30 30 
spsq Correlation Coefficient -.212 .496
**
 .504
**
 1.000 
Sig. (2-tailed) .107 .000 .000 . 
N 30 30 30 30 
**. Correlation is significant at the 0.01 level (2-tailed). 
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Appendix R 
SPSS Output: Within group premorbid functioning, anxiety, and depression 
correlations (control group) 
 
Correlations 
 topf anxiety depression spsq 
Kendall's tau_b topf Correlation Coefficient 1.000 -.061 -.232 -.226 
Sig. (2-tailed) . .661 .115 .096 
N 29 29 29 29 
anxiety Correlation Coefficient -.061 1.000 .487
**
 .505
**
 
Sig. (2-tailed) .661 . .001 .000 
N 29 29 29 29 
depression Correlation Coefficient -.232 .487
**
 1.000 .567
**
 
Sig. (2-tailed) .115 .001 . .000 
N 29 29 29 29 
spsq Correlation Coefficient -.226 .505
**
 .567
**
 1.000 
Sig. (2-tailed) .096 .000 .000 . 
N 29 29 29 29 
**. Correlation is significant at the 0.01 level (2-tailed). 
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Appendix S 
SPSS Output: Kruskal-Wallis H test and contingency tables for TOMM, 
SRSI, and WMT 
TOMM 
 
Group 
Total Control Malinger 
TOMM Pass Count 30 8 38 
% within Group 100.0% 26.7% 63.3% 
Fail Count 0 22 22 
% within Group 0.0% 73.3% 36.7% 
Total Count 30 30 60 
% within Group 100.0% 100.0% 100.0% 
 
 
WMT 
 
Group 
Total Control Malinger 
WMT Pass Count 30 6 36 
% within Group 100.0% 20.0% 60.0% 
Fail Count 0 24 24 
% within Group 0.0% 80.0% 40.0% 
Total Count 30 30 60 
% within Group 100.0% 100.0% 100.0% 
 
 
Test Statisticsa,b 
 TOMM SRSI WMT 
Chi-Square 34.158 39.333 39.333 
df 1 1 1 
Asymp. Sig. .000 .000 .000 
a. Kruskal Wallis Test 
b. Grouping Variable: Group 
SRSI 
 
Group 
Total Control Malinger 
SRSI Pass Count 30 6 36 
% within Group 100.0% 20.0% 60.0% 
Fail Count 0 24 24 
% within Group 0.0% 80.0% 40.0% 
Total Count 30 30 60 
% within Group 100.0% 100.0% 100.0% 
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Appendix T 
SPSS Output: Kruskal-Wallis H for SPCS  
 
Report 
Group total SPCS Pseudo total 
Pseudo 
frequency 
Control Mean 9.57 1.87 1.57 
N 30 30 30 
Std. Deviation 6.317 2.556 2.046 
Malinger Mean 51.87 15.17 9.13 
N 30 30 30 
Std. Deviation 21.654 10.403 4.890 
Total Mean 30.72 8.52 5.35 
N 60 60 60 
Std. Deviation 26.552 10.068 5.326 
 
 
Test Statisticsa,b 
 total SPCS Pseudo total 
Pseudo 
frequency 
Chi-Square 42.358 30.870 29.684 
df 1 1 1 
Asymp. Sig. .000 .000 .000 
a. Kruskal Wallis Test 
b. Grouping Variable: Group 
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Appendix U 
SPSS Output: Kruskal-Wallis H of pseudo items 
 
 
Test Statisticsa,b 
 f1 f2 f3 f4 f5 f6 f7 f8 f9 f10 f11 f12 f13 f14 f15 totalF freqF 
Chi-
Square 
33.621 1.896 20.248 10.316 15.674 15.698 17.695 15.243 5.789 12.786 19.259 25.052 18.201 31.046 29.545 30.870 29.684 
df 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
Asymp. 
Sig. 
.000 .169 .000 .001 .000 .000 .000 .000 .016 .000 .000 .000 .000 .000 .000 .000 .000 
a. Kruskal Wallis Test 
b. Grouping Variable: group 
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Appendix V 
SPSS Output: ROC curves and classification statistics  
SPCS Total Score: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Area Under the Curve 
Test Result Variable(s):   SPCS   
Area Std. Error
a
 Asymptotic Sig.
b
 
Asymptotic 95% Confidence Interval 
Lower Bound Upper Bound 
.989 .009 .000 .972 1.000 
a. Under the nonparametric assumption 
b. Null hypothesis: true area = 0.5 
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Coordinates of the Curve 
Test Result Variable(s):   SPCS   
Positive if Greater 
Than or Equal 
To
a
 Sensitivity 1 - Specificity 
-1.00 1.000 1.000 
1.00 1.000 .967 
2.50 1.000 .900 
3.50 1.000 .867 
4.50 1.000 .833 
5.50 1.000 .733 
6.50 1.000 .700 
7.50 1.000 .567 
8.50 1.000 .467 
9.50 1.000 .400 
10.50 1.000 .300 
12.00 1.000 .233 
13.50 1.000 .200 
14.50 1.000 .167 
16.00 1.000 .133 
17.50 .967 .133 
19.50 .933 .133 
21.50 .933 .100 
22.50 .933 .067 
23.50 .900 .067 
25.50 .900 .000 
28.00 .867 .000 
29.50 .833 .000 
32.50 .800 .000 
36.50 .767 .000 
38.50 .667 .000 
41.50 .633 .000 
45.00 .600 .000 
46.50 .567 .000 
48.00 .533 .000 
51.50 .467 .000 
56.00 .400 .000 
59.50 .333 .000 
63.00 .267 .000 
67.50 .233 .000 
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70.50 .200 .000 
73.50 .167 .000 
81.50 .133 .000 
88.50 .100 .000 
92.00 .033 .000 
95.00 .000 .000 
a. The smallest cutoff value is the minimum 
observed test value minus 1, and the largest 
cutoff value is the maximum observed test value 
plus 1. All the other cutoff values are the averages 
of two consecutive ordered observed test values. 
 
Pseudo Symptoms Total Score: 
 
 
 
 
 
 
 
Area Under the Curve 
Test Result Variable(s):   total pseudo   
Area Std. Error
a
 Asymptotic Sig.
b
 
Asymptotic 95% Confidence Interval 
Lower Bound Upper Bound 
.914 .040 .000 .835 .992 
The test result variable(s): totalF has at least one tie between the positive actual 
state group and the negative actual state group. Statistics may be biased. 
a. Under the nonparametric assumption 
b. Null hypothesis: true area = 0.5 
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Coordinates of the Curve 
Test Result Variable(s):   total pseudo  
Positive if Greater 
Than or Equal 
To
a
 Sensitivity 1 - Specificity 
-1.00 1.000 1.000 
.50 .933 .567 
1.50 .933 .367 
2.50 .900 .300 
3.50 .900 .167 
4.50 .833 .133 
6.00 .767 .133 
7.50 .733 .033 
8.50 .700 .033 
9.50 .700 .000 
10.50 .667 .000 
11.50 .633 .000 
12.50 .567 .000 
14.00 .533 .000 
15.50 .467 .000 
16.50 .400 .000 
17.50 .367 .000 
18.50 .333 .000 
19.50 .300 .000 
21.00 .200 .000 
22.50 .167 .000 
27.00 .133 .000 
32.50 .100 .000 
35.00 .067 .000 
38.00 .033 .000 
41.00 .000 .000 
 
a. The smallest cutoff value is the minimum 
observed test value minus 1, and the largest 
cutoff value is the maximum observed test value 
plus 1. All the other cutoff values are the averages 
of two consecutive ordered observed test values. 
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Frequency of Pseudo Symptoms: 
 
 
 
 
 
 
Area Under the Curve 
Test Result Variable(s):   freqF   
Area Std. Error
a
 Asymptotic Sig.
b
 
Asymptotic 95% Confidence Interval 
Lower Bound Upper Bound 
.906 .041 .000 .825 .986 
The test result variable(s): freqF has at least one tie between the positive actual 
state group and the negative actual state group. Statistics may be biased. 
a. Under the nonparametric assumption 
b. Null hypothesis: true area = 0.5 
 
Coordinates of the Curve 
Test Result Variable(s):   freqF   
Positive if Greater 
Than or Equal 
To
a
 Sensitivity 1 - Specificity 
-1.00 1.000 1.000 
.50 .933 .567 
1.50 .933 .367 
2.50 .900 .233 
3.50 .800 .167 
4.50 .733 .100 
5.50 .733 .067 
6.50 .700 .067 
7.50 .667 .000 
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8.50 .567 .000 
9.50 .533 .000 
10.50 .500 .000 
11.50 .400 .000 
12.50 .333 .000 
13.50 .233 .000 
14.50 .167 .000 
16.00 .000 .000 
 
a. The smallest cutoff value is the minimum 
observed test value minus 1, and the largest 
cutoff value is the maximum observed test value 
plus 1. All the other cutoff values are the averages 
of two consecutive ordered observed test values. 
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Appendix W 
Author guidelines for the Journal of Clinical and Experimental Neuropsychology  
About the journal 
Journal of Clinical and Experimental Neuropsychology is an international, peer reviewed 
journal, publishing high-quality, original research. Please see the journal’s Aims & Scope 
for information about its focus and peer-review policy. 
Please note that this journal only publishes manuscripts in English. 
This journal accepts the following article types: regular (Original) Articles, Review 
Articles and Critiques. 
Peer review 
Taylor & Francis is committed to peer-review integrity and upholding the highest 
standards of review. Once your paper has been assessed for suitability by the editor, it will 
then be double blind peer-reviewed by independent, anonymous expert referees. Find out 
more about what to expect during peer review and read our guidance on publishing ethics. 
Preparing your paper 
All authors submitting to medicine, biomedicine, health sciences, allied and public health 
journals should conform to the Uniform Requirements for Manuscripts Submitted to 
Biomedical Journals, prepared by the International Committee of Medical Journal Editors 
(ICMJE). 
We also refer authors to the community standards explicit in the American Psychological 
Association's (APA) Ethical Principles of Psychologists and Code of Conduct. 
Structure 
Your paper should be compiled in the following order: title page; abstract; keywords; main 
text; acknowledgements; references; appendices (as appropriate); table(s) with caption(s) 
(on individual pages); figure caption(s) (as a list). 
Word limits 
Please include a word count for your paper.  
There are no word limits for articles in this journal. 
Style guidelines 
Please refer to these style guidelines when preparing your paper, rather than any published 
articles or a sample copy. 
Please use American spelling style consistently throughout your manuscript. 
138 
 
Please use double quotation marks, except where "a quotation is 'within' a quotation". 
Please note that long quotations should be indented without quotation marks. 
The style and format of your paper should conform to the specifications given in the 
Publication Manual of the American Psychological Association (6th ed.). 
Abstracts: Authors submitting papers should note that the journal offers a choice to 
authors to publish either ordinary abstracts, or structured abstracts of between 200-300 
words. 
Structured abstracts have the advantage of being clearer for readers and facilitate better, 
appropriate indexing and citation of papers, and their essential features are below: 
 Introduction: Describe the background to the study, hypotheses, aims, objectives, 
research questions, etc. Method: Include outline of the methodology and design of 
experiments; materials employed and subject/participant numbers with basic relevant 
demographic information; the nature of the analyses performed. 
 Results: Outline the important and relevant results of the analyses. 
 Conclusions: State the basic conclusions and implications of the study. State, clearly 
and usefully, if there are implications for management, treatment or service delivery. 
Note: Any clinical implications should be clearly stated. Avoid abbreviations, diagrams, 
and references to the text in the abstract.  
Formatting and templates 
Papers may be submitted in any standard format, including Word and LaTeX. Figures 
should be saved separately from the text. To assist you in preparing your paper, we provide 
formatting templates. 
A LaTeX template is available for this journal. 
Word templates are available for this journal. Please save the template to your hard drive, 
ready for use. 
If you are not able to use the templates via the links (or if you have any other template 
queries) please contact authortemplate@tandf.co.uk 
If any assistance is needed with uploading files to our submission system, please feel free 
to email the Editorial Assistant. 
References 
Please use this reference style guide when preparing your paper. An EndNote output style 
is also available to assist you. 
Checklist: what to include 
1. Author details. Please ensure everyone meeting the International Committee of 
Medical Journal Editors (ICMJE) requirements for authorship is included as an author 
139 
 
of your paper. Please include all authors’ full names, affiliations, postal addresses, 
telephone numbers and email addresses on the title page. Where available, please also 
include ORCID identifiers and social media handles (Facebook, Twitter or LinkedIn). 
One author will need to be identified as the corresponding author, with their email 
address normally displayed in the article PDF (depending on the journal) and the online 
article. Authors’ affiliations are the affiliations where the research was conducted. If 
any of the named co-authors moves affiliation during the peer-review process, the new 
affiliation can be given as a footnote. Please note that no changes to affiliation can be 
made after your paper is accepted. Read more on authorship. 
2. A structured or unstructured abstract of more than 200 and no more than 300 words. A 
structured abstract should cover (in the following order): Introduction, Results and 
Conclusions. Read tips on writing your abstract. 
3. Graphical abstract (Optional). This is an image to give readers a clear idea of the 
content of your article. It should be a maximum width of 525 pixels. If your image is 
narrower than 525 pixels, please place it on a white background 525 pixels wide to 
ensure the dimensions are maintained. Save the graphical abstract as a .jpg, .png, or .gif. 
Please do not embed it in the manuscript file but save it as a separate file, labelled 
GraphicalAbstract1. 
4. You can opt to include a video abstract with your article. Find out how these can help 
your work reach a wider audience, and what to think about when filming. 
5. Up to five keywords. Read making your article more discoverable, including 
information on choosing a title and search engine optimization. 
6. Funding details. Please supply all details required by your funding and grant-awarding 
bodies as follows:  
For single agency grants: This work was supported by the [Funding Agency] under 
Grant [number xxxx].  
For multiple agency grants: This work was supported by the [funding Agency 1]; under 
Grant [number xxxx]; [Funding Agency 2] under Grant [number xxxx]; and [Funding 
Agency 3] under Grant [number xxxx]. 
7. Disclosure statement. This is to acknowledge any financial interest or benefit that has 
arisen from the direct applications of your research. Further guidance on what is a 
conflict of interest and how to disclose it. 
8. Geolocation information. Submitting a geolocation information section, as a separate 
paragraph before your acknowledgements, means we can index your paper’s study area 
accurately in JournalMap’s geographic literature database and make your article more 
discoverable to others. 
9. Supplemental online material. Supplemental material can be a video, dataset, fileset, 
sound file or anything which supports (and is pertinent to) your paper. We publish 
supplemental material online via Figshare. Find out more about supplemental material 
and how to submit it with your article. 
10. Figures. Figures should be high quality (1200 dpi for line art, 600 dpi for grayscale and 
300 dpi for color, at the correct size). Figures should be saved as TIFF, PostScript or 
EPS files. More information on how to prepare artwork. 
11. Tables. Tables should present new information rather than duplicating what is in the 
text. Readers should be able to interpret the table without reference to the text. Please 
supply editable files. 
12. Equations. If you are submitting your manuscript as a Word document, please ensure 
that equations are editable. More information about mathematical symbols and 
equations. 
13. Units. Please use SI units (non-italicized). 
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Using third-party material in your paper 
You must obtain the necessary permission to reuse third-party material in your article. The 
use of short extracts of text and some other types of material is usually permitted, on a 
limited basis, for the purposes of criticism and review without securing formal permission. 
If you wish to include any material in your paper for which you do not hold copyright, and 
which is not covered by this informal agreement, you will need to obtain written 
permission from the copyright owner prior to submission. More information on requesting 
permission to reproduce work(s) under copyright. 
Disclosure statement 
Please include a disclosure of interest statement, using the subheading "Disclosure of 
interest." If you have no interests to declare, please state this (suggested wording: The 
authors report no conflicts of interest). For all NIH/Wellcome-funded papers, the grant 
number(s) must be included in the disclosure of interest statement. Read more on declaring 
conflicts of interest. 
Clinical Trials Registry 
In order to be published in a Taylor & Francis journal, all clinical trials must have been 
registered in a public repository at the beginning of the research process (prior to patient 
enrolment). Trial registration numbers should be included in the abstract, with full details 
in the methods section. The registry should be publicly accessible (at no charge), open to 
all prospective registrants, and managed by a not-for-profit organization. For a list of 
registries that meet these requirements, please visit the WHO International Clinical Trials 
Registry Platform (ICTRP). The registration of all clinical trials facilitates the sharing of 
information among clinicians, researchers, and patients, enhances public confidence in 
research, and is in accordance with the ICMJE guidelines. 
Complying with ethics of experimentation 
Please ensure that all research reported in submitted papers has been conducted in an 
ethical and responsible manner, and is in full compliance with all relevant codes of 
experimentation and legislation. All papers which report in vivo experiments or clinical 
trials on humans or animals must include a written statement in the Methods section. This 
should explain that all work was conducted with the formal approval of the local human 
subject or animal care committees (institutional and national), and that clinical trials have 
been registered as legislation requires. Authors who do not have formal ethics review 
committees should include a statement that their study follows the principles of the 
Declaration of Helsinki. 
Consent 
All authors are required to follow the ICMJE requirements on privacy and informed 
consent from patients and study participants. Please confirm that any patient, service user, 
or participant (or that person's parent or legal guardian) in any research, experiment, or 
clinical trial described in your paper has given written consent to the inclusion of material 
pertaining to themselves, that they acknowledge that they cannot be identified via the 
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paper; and that you have fully anonymized them. Where someone is deceased, please 
ensure you have written consent from the family or estate. Authors may use this Patient 
Consent Form, which should be completed, saved, and sent to the journal if requested. 
Health and safety 
Please confirm that all mandatory laboratory health and safety procedures have been 
complied with in the course of conducting any experimental work reported in your paper. 
Please ensure your paper contains all appropriate warnings on any hazards that may be 
involved in carrying out the experiments or procedures you have described, or that may be 
involved in instructions, materials, or formulae. 
Please include all relevant safety precautions; and cite any accepted standard or code of 
practice. Authors working in animal science may find it useful to consult the International 
Association of Veterinary Editors' Consensus Author Guidelines on Animal Ethics and 
Welfare and Guidelines for the Treatment of Animals in Behavioural Research and 
Teaching. When a product has not yet been approved by an appropriate regulatory body for 
the use described in your paper, please specify this, or that the product is still 
investigational. 
Submitting your paper 
This journal uses ScholarOne Manuscripts to manage the peer-review process. If you 
haven't submitted a paper to this journal before, you will need to create an account in the 
submission centre. Please read the guidelines above and then submit your paper in the 
relevant author centre where you will find user guides and a helpdesk. 
If you are submitting in LaTeX, please convert the files to PDF beforehand (you may also 
need to upload or send your LaTeX source files with the PDF). 
Please note that Journal of Clinical and Experimental Neuropsychology uses Crossref™ to 
screen papers for unoriginal material. By submitting your paper to Journal of Clinical and 
Experimental Neuropsychology you are agreeing to originality checks during the peer-
review and production processes. 
On acceptance, we recommend that you keep a copy of your Accepted Manuscript. Find 
out more about sharing your work. 
Publication charges 
There are no submission fees or page charges for this journal. 
Color figures will be reproduced in color in your online article free of charge. If it is 
necessary for the figures to be reproduced in color in the print version, a charge will apply. 
Charges for color figures in print are £250 per figure ($395 US Dollars; $385 Australian 
Dollars; €315). For more than 4 color figures, figures 5 and above will be charged at £50 
per figure ($80 US Dollars; $75 Australian Dollars; €63). Depending on your location, 
these charges may be subject to local taxes. 
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Copyright options 
Copyright allows you to protect your original material, and stop others from using your 
work without your permission. Taylor & Francis offers a number of different license and 
reuse options, including Creative Commons licenses when publishing open access. Read 
more on publishing agreements. 
Complying with funding agencies 
We will deposit all National Institutes of Health or Wellcome Trust-funded papers into 
PubMedCentral on behalf of authors, meeting the requirements of their respective open 
access (OA) policies. If this applies to you, please tell our production team when you 
receive your article proofs, so we can do this for you. Check funders' OA policy mandates 
here. Find out more about sharing your work. 
Open access 
This journal gives authors the option to publish open access via our Open Select publishing 
program, making it free to access online immediately on publication. Many funders 
mandate publishing your research open access; you can check open access funder policies 
and mandates here.  
Taylor & Francis Open Select gives you, your institution or funder the option of paying an 
article publishing charge (APC) to make an article open access. Please contact 
openaccess@tandf.co.uk if you would like to find out more, or go to our Author Services 
website. 
For more information on license options, embargo periods and APCs for this journal please 
search for the journal in our journal list. 
My Authored Works 
On publication, you will be able to view, download and check your article’s metrics 
(downloads, citations and Altmetric data) via My Authored Works on Taylor & Francis 
Online. This is where you can access every article you have published with us, as well as 
your free eprints link, so you can quickly and easily share your work with friends and 
colleagues. 
We are committed to promoting and increasing the visibility of your article. Here are some 
tips and ideas on how you can work with us to promote your research. 
Article reprints 
You will be sent a link to order article reprints via your account in our production system. 
For enquiries about reprints, please contact the Taylor & Francis Author Services team at 
reprints@tandf.co.uk. You can also order print copies of the journal issue in which your 
article appears. 
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Paper Three: Reflective Account 
Reflections on the research journey 
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ABSTRACT  
 
The final part of this thesis is a review and commentary on the process of 
undertaking the project starting with the selection of a topic through to writing up 
ready for submission. The researcher kept a journal throughout the project to 
document and record various experiences and supervisory discussions, and using 
Schon’s (1983) model of reflection, these ‘reflections in action’ were used to 
develop ‘reflections on action’. Difficulties encountered by the researcher are 
discussed and considered within the context of the current challenges faced by 
clinicians working in the NHS. The overall experience of completing this thesis was 
concluded to be a positive learning opportunity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract word count: 105  
Paper 3 word count: 1,659  
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Reflective Account 
Introduction  
Schon’s (1983) model of reflection states that there are two types of reflective 
practice. The first is termed ‘reflection in action’, and the second ‘reflection on 
action’. Reflection in action involves experiencing reflection in the moment and 
making adjustments whilst practicing. Reflection on action is completed at a later 
point and involves processing something that has already happened and 
considering if anything would be done differently next time. This reflective account 
will aim to reflect on action, by making use of a research journal that was kept 
throughout the thesis journey and could be said to contain some in action 
reflections. I will now consider and discuss the process of undertaking this thesis 
and reflect upon some of the challenges that I encountered.  
 
Selecting a research topic and developing ideas 
I was initially interested in a thesis topic that concerned neuropsychology as my 
undergraduate degree was dual honours in Psychology and Neuroscience. Up 
until the point of starting on clinical training I had not had the opportunity to apply 
the neuroscience side of my degree. Prior to starting clinical training, as an 
Assistant Psychologist working in forensic services, I had always had an interest in 
psychometric testing and had experience of administering a range of measures.  
In the first year the Assessing Psychological Processes module involved 
developing an understanding of neuroanatomy and psychological processes with 
regards to neuropsychological assessment. I took the opportunity to discuss 
research projects with visiting clinicians delivering teaching sessions, one of whom 
became the clinical research supervisor for the project. I explored the topic of 
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assessing malingering and symptom validity in traumatic brain injury (TBI), and 
more specifically in patients with a diagnosis of post concussion syndrome (PCS). 
I initially looked into validating an existing self-report measure of symptom 
severity, The Post Concussive Symptom Questionnaire (PCSQ; Lees-Haley, 
1992). However, following an exploration of the literature a need was identified for 
a new measure to be developed that had included both genuine and pseudo 
symptoms of PCS.    
 
Literature review   
When developing a research question for the literature review paper into the use 
of validity measures in mild TBI, I initially found that searches were generating 
thousands of research papers. I decided to narrow the research question to 
specifically investigate the use of symptom validity tests (SVTs) when assessing 
for PCS. I acknowledged that there are SVT measures that may have been 
validated in mTBI populations that could be applied to assessing validity in PCS, 
however, I decided to concentrate the review on papers that had focussed 
specifically on the use of SVTs in PCS. In the same way that a literature review 
may focus specifically on interventions in stroke as opposed to all non-traumatic 
acquired brain injury.  
 
With no prior experience of writing a full literature review paper I was 
somewhat surprised by the amount of time and effort required to identify, consider 
and critically appraise relevant papers. This led to a deviation from my original 
research gantt chart, and on reflection, when planning future projects I will allocate 
more time to reviewing the existing literature.  
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Empirical paper  
The approval process  
Following gaining approval from the peer review panel at Staffordshire University, 
ethical approval was sought from an NHS Research Ethics Committee (NHS REC) 
through the submission of an Integrated Research Application System (IRAS) 
application. At the time of submission to the NHS REC, changes were being made 
to the process of gaining ethical approval. The changes mainly concerned the 
Health Research Authority (HRA) having more of a role in the application process, 
and were designed to speed up the process of applying for ethical approval by 
removing duplicate application routes through multiple research and development 
teams. However, when the IRAS application for this research project was first 
submitted the system was mid-change and a backlog of applications built up 
causing delays in getting ethical approval and commencing with the research. 
Data collection with non-clinical participants was able to be commenced after NHS 
REC approval was given on 08/09/16. In order to approach potential clinical 
participants however, HRA approval was required. Apologies were sent from the 
HRA as there were significant delays obtaining this approval; the approval letter 
was not received until the 05/12/16. As the original IRAS application had stated 
that local Research and Development (R&D) approval was required, this then had 
to be completed following receipt of the HRA approval letter. R&D approval for the 
identified research site that responded positively to my enquiries about supporting 
with recruitment of clinical participants was finally granted on 09/02/17. This left 
very little time to attempt to collect a clinical sample, which is discussed in more 
detail below. 
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Difficulties with recruitment 
The main challenge that was encountered in the completion of this thesis was 
recruiting a clinical sample. In order to avoid potential ethical dilemmas, the 
inclusion and exclusion criteria was agreed with the NHS REC whereby patients 
involved in litigation or receiving benefits as a result of their head injury were 
excluded from participating in the research. This significantly reduced the number 
of potential participants. A number of clinicians and services were contacted to 
support with recruitment to the research study. Of those who responded, just one 
service suggested that they may have been able to support recruitment of mTBI 
patients. Other clinicians stated a number of reasons as to why recruitment from 
their service was not possible which included service reorganisation, meaning 
mTBI patients were not generally picked up by the service. Time was another 
factor, whereby as more demands were placed on clinicians in NHS services, they 
were less able to provide support in research projects. One specialist Accident & 
Emergency Neuropsychology partnership service for individuals with mTBI was 
identified, however, my repeated attempts to get in touch with the 
Neuropsychology team there were unsuccessful. This may be reflective of a 
changing NHS. Services are pressured to see more patients with smaller teams, 
meaning that the more severe patients are prioritised, and the mild TBI patients fall 
through the rehab net. Clinicians also have less time to engage with research. A 
survey carried out by ComRes (Association of Medical Research Charities, 2013) 
with 392 GPs, hospital doctors and nurses in the NHS, identified similar barriers to 
taking part in research – including lack of time (62%), funding (30%), practical 
support (27%) and difficulties navigating regulation (24%). Despite universal 
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agreement that research in the NHS is important in developing and improving 
treatments for patients; financial pressures on time and a drive to cut waiting lists 
means that research has become less of a priority for clinicians. This may be 
problematic if the NHS is to compete with private providers to become an 
innovative research organisation focused on driving improvements in patient care. 
 
During a supervision meeting to review the raw data, I had a discussion 
with my clinical research supervisor about the possibility of being less specific with 
the recruitment of clinical participants and opening up the criteria to moderate-
severe TBI patients. There were a couple of issues with this however. Firstly this 
would have involved making changes to the research protocol and submitting 
changes to ethics, and re-contacting neuropsychology services to seek support 
with recruitment, which given the late stage of the research and the need to start 
writing up, may not have been achievable. Secondly, as identified in the appraisal 
of Tsandis et al. (2008) in part 1 of this thesis, it is possible that moderate-severe 
TBI patients have deficits in self-awareness, and so their participation as a clinical 
sample could be considered problematic as symptom reporting requires self-
awareness as well as self-report.  
 
If the project were to be run again, and the inclusion and exclusion criteria 
were altered to allow those seeking compensation and disability benefit to 
participate, recruitment may be an easier task. A lot of research that is carried out 
with mTBI patients and performance/symptom validity testing takes place in the 
United States, and a large percentage is with military populations and in private 
clinics. It could be argued that the ethical procedures for independent clinical 
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practices are not as stringent as in the NHS. Many research papers investigating 
symptom validity testing make use of archival data of groups of individuals 
involved in litigation. However, the extent to which participants have given consent 
to their responses being used for research purposes is unknown. 
 
Closing reflections  
In summary, the process of developing and writing this thesis has been frustrating 
at times, and I frequently felt that I had very little control over the project (with 
regards to relying on ethical bodies, clinical services, and clinicians) yet I also held 
all of the responsibility. Looking back however, it is important to also recognise 
what was achieved in completing this thesis. I successfully recruited 60 
participants, a number that seemed slightly daunting at the beginning given that 
meeting with each participant involved completing a battery of psychometric 
measures, plus time to score and interpret their responses. I found some exciting 
initial results for the new measure, and although its validation with a clinical 
sample is still required, it compared favourably to established measures currently 
used in clinical services.   
To conclude, the completion of this thesis was experienced overall as a 
positive learning opportunity, despite some of the difficulties that were met along 
the journey to submission.   
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